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nAbstract
The present Thesis is introduced with a discussion of reverse transcription polymerase chain 
reaction (RT-PCR) based analysis of TCRBV regions, including the description of a panel of 
primers. Using this primer panel, we analysed for TCR clonality in progressive versus 
regressive parts of partially regressive primary melanoma lesions (Paper 1). The main 
conclusion drawn from this study is that clonotypic T cells were present in both regressive 
and progressive parts of the same lesions. However, sequencing of “non clonal” BV-regions 
demonstrated that most of them were not polyclonal by nature but oligoclonal e.g. that in 
some cases all transcripts were of the same length or only a limited number of BJ regions 
were used. This indicated that some T-cell clones were left undetected by direct sequencing.
To facilitate full and detailed analysis of T-cell clonotypes in the infiltrates we aimed 
at establishing a suitable method for the detection of clonally expanded T cells. Denaturing 
gradient gel electrophoresis (DGGE) was chosen because this method is highly sensitive and 
excludes laborious steps that are obligatory in almost all other methods dealing with the 
detection of TCR clonality (Paper 2).
We applied the DGGE based method to analyse for in situ T-cell clonality in 6 
subcutaneous melanoma lesions from two patients. The results demonstrated two important 
characteristics of in situ TIL in melanoma. First, the infiltrate constitutes an exceedingly high 
number of different T-cell clones, and second, the T-cell response appears to be executed by 
local T cells that do not enter the periphery (Paper 3).
The final study deals with a comparative analysis of in situ T cells and T cells 
propagated in vitro, demonstrating that standard in vitro culture conditions do not support the 
growth of in vivo expanded T-cell clones (Paper 4).
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Introduction to the cell mediated immune system
The vertebrate body offers an ideal breeding ground for a variety of virus and bacteria. The immune 
system deals with this challenge in a controlled fashion, clearing the body for virulent pathogens. The 
immune system can roughly be divided into innate and adaptive branches. Whereas the innate immune 
system in general recognises posttranslational modifications on infected cells or on pathogens 
themselves, adaptive immune responses are characterised by the specific receptor mediated 
recognition of antigen or antigen fragments. In general, adaptive immunity is considered as a second 
line of defence, dealing with tiie pathogens that are not cleared from the body by innate immunity.
Another characteristic of adaptive immunity is the capacity to memorise and respond rapidly 
to a second exposure to antigen. B cells and T cells are the most important cell types of adaptive 
immunity. B cells control humoral immunity by the production of antibodies (Ab) whereas T cells are 
involved in a much broader spectrum of cellular immunity. Where B cells recognise native antigen, T 
cells are restricted to the recognition of antigen fi-agments presented in the context of MHC molecules. 
As T-cell responses are the main topic of this Thesis, the following introduction will focus on this cell 
type.
The Major Histocompatibiiity Complex (MHC)
The initiation of a T-cell response is dependent upon the processing and presentation of the antigenic 
peptide in the context of Major Histocompatibility Complex (MHC) class I or class H molecules. Most 
nucleated cells express class T molecules, whereas class H molecules are expressed mainly by 
speciahsed antigen presenting cells (APC): macrophages, B cells, and dendritic cells (DCs). In general 
peptides derived from intracellular antigens are presented to CD8 positive (CD8^ T cells in the 
context of class I molecules, while peptides derived from extracellular antigens are presented to CD4 
positive (CD4^ T cells in the context of class II molecules.
The MHC genes are polygenic. This means that there are several different MHC class I and 
class n  genes, encoding proteins with different peptide specificities. Furthermore, the MHC genes are 
the most polymorphic genes known, implying that each MHC gene exists as several allelic variants.
Class I MHC: Structure aud peptide preseutatiou
Cells of higher vertebrates have evolved a highly complex enzymatic system that allows intracellular 
proteins to be processed into small peptide fragments and presented on the cell surface, available for 
immune surveillance. The presentation of these peptides occurs in the context of MHC class I 
molecules which consist of two non-covalently associated proteins, the membrane spanning 
glycosylated a-chain (heavy chain; HC) and the smaller (32-microglobulin (P2M). The Class I 
molecules in humans are encoded by three class I a-chain genes (HLA-A, -B, and -C) and have four 
domains; the (3zM and three domains of HC, a%, a:, and as of which a% and a 2 together form the 
peptide binding groove (1). Both the (32M and the HC are co-translationally inserted into the 
endoplasmatic reticulum (ER) in a signal-sequence dependent fashion upon which the HC assembles 
with the membrane bound chaperone calnexin until complexing with P2M (2). Another chaperone, 
calreticulin, binds the class I molecule prior to peptide loading, the peptides being translocated to the 
lumen of ER from the cytosol by the transporters associated with antigen processing (TAP). During 
the association of the class I molecule and TAP which is facilitated by the ER resident protein tapasin.
peptides are loaded onto the class I molecule (3). Peptide binding stabilises the MHC molecule and 
induces its release from the ER after which the class I molecule migrates to the surface (4).
The peptides binding to class I molecules encompass 8-12 amino acids. Cytosolic proteins are 
targeted for degradation by the attachment of ubiquitin making them susceptible for degradation by the 
proteasome complex (2).
Class n  MHC: Structure and peptide presentation
MHC class n  molecules in general bind and present peptides derived from exogeneous proteins. The 
class n  molecule is composed of two transmembrane glycoprotein chains, the a- and the (3-chain. As 
for the class I genes there are three pairs of a- and P chain genes, HLA-DR, -DP, and DQ. However, 
the HLA-DR locus encodes an additional (3-chain protein which can pair with the DRa chain implying 
that the three sets of class II genes may give rise to four different class II molecules (5). Furthermore, 
the possible paring of paternal and maternal class II chains adds to the number of different Class II 
molecules.
Each chain of the class II molecule has two domains, ai and a% (for the a-chain) and pi and Pz 
(for the p chain), together forming a four-domain structure similar to the class I molecule. However, 
the peptide binding groove of the class II molecule is open at both ends, and the peptides binding to 
the class II molecule are generally at least 13 amino acids in length but may be much longer. Prior to 
binding of peptide, the class II molecule assembles in the ER with the Invariant chain (li) making a 
nonameric complex (apE)] in which the peptide binding groove of the class II molecule is occupied 
by the CLIP region of the li. The presence of the invariant chain directs the complex to the endosomes, 
in which exogenous proteins are degraded after capture from the environment by receptor mediated 
endocytosis, phagocytosis or macropinocytosis (6). The removal of the CLIP peptide and the favoured 
binding of peptides with high affinity are facilitated by the MHC encoded HLA-DM molecule (7; 8). 
After assembly in the endosome the class II MHC/peptide complexes traffic to the cell surface, 
although the route by which the class II molecule reaches the cell surface is not fully understood (6).
The T cell
T-ceU functions
The function of T cells is to recognise the presence of pathogens in the body and to respond 
accordingly, either by direct elimination of the pathogen or by activating other parts of the immune 
system to clear the pathogen. T cells do not recognise native antigen but small antigen fragments 
(peptides) presented in the context of MHC molecules. This dual specificity for both MHC and antigen 
is accomplished by the T-cell receptor (TCR), consisting of an ap- or a yô-heterodimer (9).
T cells constitute approximately 70 % of the peripheral blood lymphocytes in adult humans 
and are responsible for the majority of the cell mediated immune responses that depend on cell to cell 
interactions. The main types of T cells are the cytotoxic T cells (CTL), and T helper cells (Th). In 
general these T-cell subsets can be distinguished phenotypically by the expression of the CD4 or the 
CDS molecules, the CD8 molecule being expressed by the CTL, whereas the CD4 molecule is 
expressed on Th cells.
The most direct function of the different T-cell types is exerted by the CTL which recognise 
endogeneous antigens, in general derived fix>m intracellular pathogens. Upon recognition and 
activation CTL are capable of killing the infected cell. Killing of the target cell may be accomplished 
by the granule exocytosis mechanism, in which release of cytotoxins will generate pores in the target 
cell membrane. Cytotoxicity may also be induced by ligation of Fas ligand (FasL,CD95L) on the 
effector cell with trimeric Fas (CD95) on the target cell generating a death signal that induces 
apoptosis (10).
The Th cells can be divided into (at least) two different groups; the Thl cells (or 
inflammatory T cells) and the Th2 cells. Thl and Th2 cells in general recognise peptides derived finm 
exogeneous proteins presented in the context of class II MHC molecules. The actions of Thl and Th2 
cells are exerted by means of cytokine production by which the Thl cells activate macrophages during 
inflammation (by secretion of interleukin (IL) 2, interferon-P (IFN-P), and interferon-y (IFN-y)), 
whereas Th2 cells activate B cells by the secretion of IL-4, IL-5, IL-6 and BL-IO (11).
T-cell development
T cells are derived from pluripotent stem cells in the bone marrow. Committed T-cell precursors 
migrate to the thymus where maturation and rearrangement of the TCR gene segments take place. 
Early T-cell development is characterised by expansion and differentiation of thymocytes which do 
not yet express mature TCRs on their cell surface. Immature pro-thymocytes arriving at the thymus 
express neither the CD4 nor the CDS molecule (CD4 CD8 ; double negative (DN)). During later steps 
of T-cell development both CD4 and CDS are expressed (CD4^CD8^; double positive (DP)) and the T 
cell gets committed to express the yô or the a p  TCR, and to lose the expression of either the CD4 or 
the CDS molecule (Fig. 1). Most yô T cells are, however, of DN phenotype and the mechanisms 
underlymg the commitment to the a p  or the yô Imeage are not fully delmeated although successful yô 
rearrangement probably influences the lineage fate (12).
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Figure 1. T-cell development and differentiation in the thymus (13).
T cells that react against self-peptides are being eliminated in the thymus, a process referred 
to as negative selection. In a second selection step in the thymus, TCRs are positively selected for low 
affinity against MHC/self-peptides. Like with the negative selection, T cells that are unable to exceed 
a positive affinity/avidity threshold undergo apoptosis (13-15). Only approximately 2-5% of the T 
cells that enter the thymus go successfully through the steps of rearrangement and selection and 
subsequently reach the periphery as naïve T cells (13; 16).
The TCR and TCR rearrangement
Antigen recognition by T cells is mediated through the TCR, a clonally distributed heterodimer, in 
most T cells consisting of an a  and a p chain, although a small fraction uses a yô heterodimer instead 
(9). Both the a  and P chains are glycoproteins with molecular weights between 40 and 60 kD. Each T 
cell expresses a clonotypic TCR on the cell surface together with the non-clonotypic members of the 
TCR signaling complex: the different chains of the CD3 complex (y, ô, e) and the ^ chain homodimer 
(Fig. 2) (17).
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Figure 2. Components of the T-cell receptor: The aP-TCR together with the y, Ô, and e chains of the 
CD3, and the ^-homodimer (18).
In the germline, each of the TCR proteins is encoded by variable (V), joining (J) and a 
constant (C) gene segment(s), and for the p chain, an additional diversity (D) segment (13). During T- 
cell maturation in the thymus the a  and p or the y and ô gene-segments are rearranged into a single 
transcriptional unit for each of the chains, encoding unique aP or yô TCR genes in each T cell. During
the rearrangement process, mediated by at least two proteins (RAG-1 and RAG-2) (19), tiie V, J, and 
D segments recombine to form a single exon adjacent to the C segment (Fig. 3).
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Figure 3_ Somatic rearrangement at the TCR a  and p locus (5).
In developing T cells TCR rearrangement is initiated at one of the P alleles, and continues on 
the other only when the first attempt is unsuccessful (20). This event in T-cell development is 
controlled by a pre-TCR complex consisting of a conventional TCR p^hain and the non-polymorphic 
pre-TCRa (pTa chain) whidi is noncovalently associated with components of CD3. The TCRp/pTa T 
cells undergo substantial proliferation and develop into the DP phenotype. Subsequently, the TCRa 
chain is rearranged and the TCRap is e^gressed on the cell sUr&ce. The TCRa rearrangements 
proceed on both diromosomes and are not halted by productive TCRa rearrangement unless the 
TCRap binds to a ligand (21), implying that a T cell may express one TCRp chain and two TCRa 
chains (22).
A limitless repertoire for antigen recognition is provided by the assortment of the various V, 
J, and D gene segments, as well as the addition or deletion of nucleotides at the junction between the
8V/J and the J/D gene segments. This so-called “N-region diversity” provides a unique DNA sequence 
for each individual T cell, forming a clonotype (13). The numbers of gene segments for the a  and p 
chains are given in Table 1. Based on homology (75% at the nucleotide level) the different Va (AV) 
and Vp (BV) segments have been confined into 32 AV families and 26 BV families. Whereas the AV 
families mostly consist of single member subfamilies, the BV families mainly consist of multi 
membered families (23), and in general there is a higher degree of homology between the different BV 
families than between the AV families.
Table 1. The numbers of gene segments encoding the aP-TCR
TCR
a P
Variable segments 81 64
Diversity segments 0 2
Joining segments 61 13
Constant segments 1 2
The numbers of the different a  and p gene segments are taken fi’om (24; 25).
T cell recognition of antigen
Simple amino acid sequence comparisons years back suggested that TCR heterodimers were Ig-like in 
structure, including regions with homologies to the Ig complementarity determining regions (CDR) 1, 
2, and 3 (26). Early studies proposed that the CDRl and CDR2 were the parts of the TCR responsible 
for interaction with the MHC molecule whereas the V-(D)-J region, equivalent to the Ig CDR3, 
contacts the peptide (27-29). Recently, the crystal structure of the TCR showed that this is not 
completely correct. The orientation of the TCR to the MHC/peptide complex reveals an interaction in 
which potentially all CDRs may in fact interact with the peptide, the MHC a-helices, or both, 
indicating that the CDR3 may not in all cases be the most prominent region for contact to the peptide 
(30; 31).
In contrast to the high affinity interactions for antibody to antigen, the TCR/MHC-peptide 
interactions are of low affinity, in the range of 10"^  to 10'  ^M (32). Additionally, part of the affinity in 
the case of the TCR is directed against the MHC molecule and is not directly related to the antigenic 
peptide. However, the low affinity of the interaction is measured as soluble complexes. The biological 
cell to cell affinity is indisputably much higher. The TCR/MHC-peptide interaction is characterised by 
a very short half hfe (33), although the cellular interactions between the T cell and the target cell may 
last for hours during which the T cell polarises the TCRs against the target cell and subsequently 
downregulates the TCR. Additionally, it has been shown that very few MHC/peptide complexes may 
induce T-cell activation (33-35), pointing to the model of serial triggering for T-cell activation (34). 
According to this model, the TCR encounters the MHC/peptide for a short time, reaches an activation 
threshold upon which the TCR is removed, and another TCR becomes activated by interaction with 
the MHC/peptide complex (34). Therefore, most likely, the ability of an MHC/peptide complex to 
induce activation in the T cell is depending on the kinetics of the MHC/TCR interaction in 
combination with the number of TCRs on the T-cell surface and the number of ligands on the target 
cell (33; 34). Furthermore, as the kinetics of the TCR/MHC interaction is an important factor, co- 
recqjtors CD4 and CD8 may modulate the outcome of the recogiitimi of antigen (36).
T-cell activation
Neither the a  nor the p chain of the TCR has large cytoplasmatic domains that might actively 
participate in intracellular signal transduction. Instead, the ligation of the TCR with the MHC/peptide 
complex leads to clustering of the TCR/CD3 together with CD45 and CD4 or CD8. Signal 
transduction is initiated by the activation of protein tyrosine kinases (PTK) of the src and syk families. 
p56*‘^  tyrosine kinase is associated with CD4/CD8 that become aggregated with the TCR/CD3 upon 
activation, and p59*^ becomes associated with the CD45 molecule that likewise cb-localises with the 
TCR/CU3 complex. This close encounter enables the p56*°^ / p59^ mediated phosphorylation of 
tyrosine residues in the immunoreceptor tyrosine-based activation motifs (TTAM) of the CD3/Ç chains 
(37). ITAMs are present in each of the CD3 subunits; once in the CD3 chains y, Ô and e, and three
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times in each of the two (-chains. The phosphorylation of ITAMs facilitate activation of the zeta- 
associated protein 70 (ZAP-70). The activation of p56*‘^ \ p59^ and Zap70 leads to the 
phosphorylation and activation of several proteins, in turn initiating a number of different signaling 
pathways (37). The nuclear targets for these signaling pathways are transcription factors, i.e., AP-1, 
NFAT (38), c-jun and ATF-2 (39; 40).
The naïve T cell requires a co-stimulatory signal in order to reach a state of proliferation and 
clonal expansion. The requirement of a co-stimulatory signal for T-cell activation confers a mode in 
which T-cell responses may be controlled. Naïve T cells that recognise antigen expressed on a cell that 
cannot provide additional co-stimulation become anergic and unable to produce IL-2 (41) even upon 
subsequent antigen presentation by APC (42). The co-stimulatory signal is provided by ligation of 
CD28 expressed by the T cell and B7-1 (CD80) or B7-2 (CD86) expressed on the APC.
APC
MHC I/U CD58CD54 CD22
^  CD72
CD28
'4/8
V TCR
CD2CD43 CDllaCD45
Signal
T cell
Figure 4. Molecules involved in TCR signal transduction (18).
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Activation and signalling of the CD28 molecule induce an increase in the expression (43) and 
stabihty of the IL-2 mRNA (44). Furthermore, CD28/B7 hgation reduces the number of TCR/MHC- 
peptide interactions necessary for T-cell activation (45), and early events in CD28-mediated signal 
transduction lead to the activation of AP-1 and NFAT thereby integrating the TCR aid CD28 
activation signals (37). The CD28/B7 ligation therefore appears to be important, if not mandatory, for 
T-cell activation. However, other surface molecules do participate in the activation of T cells (Fig. 4) 
either by directly participating in signaling, leading to activation, by inducing sustained expression of 
e.g. B-7 (46), or simply by increasing the affinity of the cell to cell interaction (47). Additionally, it 
was recently shown that the induction of effector CTL (eCTL) is mediated by signaling through the 
CD40 molecule (48; 49).
The activation of a T cell after the encounter with an MHC/peptide complex may take one of 
several possible routes, meaning that the activation threshold can be gained by interactions between a 
number of different molecules, possibly differing from cell to cell and from antigen to antigen. The 
number and character of the different molecular interactions are therefore heavily influencing the 
consequences of TCR/MHC-peptide ligation. Possibly the differential fate of these interactions is, at 
least in part, mediated through quantitative differences in the phosphorylation of the ITAM of CD3 
subunits (50; 51). That the peptide ligand is of utmost importance for the outcome of the TCR/MHC- 
peptide ligation is most clearly illustrated by the fact that agonistic peptides may, if altered at a single 
position, result in antagonistic TCR signaling and induce unresponsiveness (52).
TCR engagement with the MHC/peptide complex may therefore, depending on the antigen 
and the antigen quantity, the local environment and the state of the T cell result in activation, anergy or 
apoptosis.
12
Melanocytes and melanomas
Melanocytes originate from the neural crest and migrate to the skin during early embryonal life. 
Histologically, melanocytes are localised within the epidermal basal layer separated from each other 
by several kératinocytes (53). The prime function of melanocytes is the production of melanin, 
offering UV protection. Melanin synthesis starts with tyrosine as substrate and takes place in a special 
intracytoplasmic organelle, the melanosome. During melanin synthesis, the melanosome travels along 
the melanocytic dendrites, the end of which is eventually phagocytosed by the kératinocytes (54).
Frequently, melanomas arise from benign nevi, but also from normal skin. Although most 
cancers of the skin are non-melanoma skin cancers, melanoma is by far the most lethal. If not cured by 
surgery, melanoma is in most cases fatal.
Melanoma has been divided into four different classes based on growth characteristics and the 
confinement of growth to one or more tissue compartments (55). Class I encompasses precursor 
lesions (ordinary moles), class II the “melanoma in situ”, class EQ and class IV are primary and 
metastatic melanoma, respectively. In addition, each class is divided into subgroups on the basis of 
growth direction (superficial vs. vertical growth), localisation and tumour type (lentigo maligna 
melanoma, LMM; superficial spreading melanoma, SSM; nodular melanoma, NM; or acral 
lentigenous melanoma, ALM) (55).
Several sequential steps of genetic changes describe tumour progression from melanocyte to 
melanoma, i.e. from normal cell to cancer cell (56). Chromosomal abnormalities in melanoma involve 
chromosomes Ip, 6q, 7q, 9p, lOq, 1 Iq, 22, and Y (57; 58). Some of the genetic changes harboured in 
malignant melanoma have been characterised in more detail, the most h-equent being deletions or 
mutations of the pi 6 (59), PTEN (60), and beta-catenin genes (61). Furthermore, other less frequent 
genetic changes have been described (62; 63) indicating that tumour initiation and promotion may take 
one of several pathways.
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Melanoma immunology
The past decade has unveiled new insights into the role of T lymphocytes in the host's immune 
response to cancer in general and to melanoma in particular (64). Several melanoma associated 
antigens (MAA) recognised by T cells have been characterised, and a number of HLA class I and class 
n  restricted peptides have been identified (65). These antigens can be divided into three different 
groups: tumor-associated testis specific antigens, melanocyte differentiation antigens, and mutated or 
aberrantly expressed antigens (Table 2). Several of these proteins give rise to more than one antigenic 
peptide; the number of known melanoma associated peptides that can induce killing by CTL has 
exceeded thirty and is still increasing. Furthermore, most studies concerned with the isolation and 
characterisation of melanoma associated proteins have been carried out using melanoma cells 
expressing the HLA-A 1 or the HLA-A2.1 allele. Therefore, even if no additional melanoma associated 
proteins will be discovered, the antigenic peptides derived fi’om the known proteins will increase as 
more restriction elements are studied. Some of the peptides have only been shown to induce 
cytotoxicity against peptide loaded cells, and it is not known whether these peptides are actually 
processed and presented naturally. Nevertheless, it is evident that melanoma cells do express a number 
of proteins that give rise to antigenic peptides.
In line with these findings, clinical data indicate that the immune system is essential in the 
control of tumor growth. A brisk infiltration of lymphocytes is associated with a favourable prognosis 
(55) and complete or partial regression of primary melanoma occurs quite fi-equently (66). Cytotoxic 
T-cell lines and clones which recognise autologous melanoma cells in an HLA restricted manner have 
been established in several laboratories (67-69), and melanoma specific cytotoxic T-cell precursors 
have been detected in the blood of melanoma patients (70-72).
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Table 2. Antigenic epitopes of melanoma-associated antigens recognized by CTL (Kirkin et al., 1998).
Antigen HLA class I Epitope Sequence References
Cancer/testis-specific antigens
MAGE-Al A1 161-169 EADPTGHSY (73)
Cwl6 230-238 SAYGEPRKL (74)
MAGE-A2 A2 112-120") KMVELVHFL (75)
A2 157-166") YLQLVFGffiV (75)
MAGE-A3 A1 168-176 EVDPIGHLY (76)
A2 271-279") FLWGPRALV (77)
A24 195-203") IMPKAGLLI (78)
B44 167-176") MEVDPIGHLY (79)
BAGE Cwl6 2-10 AARAVFLAL (80)
GAGE-1 Cw6 9-16 YRPRPRRY (77)
FRAME A24 301-309 LYVDSLFFL (81)
NY-ESO-1 A2 157-165 SLLMWITQC (82)
A2 157-167 SLLMWITQCFL (82)
A2 155-163 QLSLLMWTT (82)
Melanocyte differentiation antigens
gplOO A2 154-162 KTWGQYWQV (83)
A2 209-217 ITDQVPFSV (83)
A2 280-288 YLEPGPVTA (83)
A2 457-466 LLDGTATLRL (84)
A2 476-485 VLYRYGSFSV (83)
A3 17-25 ALLAVGATK (85)
MART-1 A2 27-35 AAGIGILTV (86)
A2 26-35 EAAGIGILTV (87)
A2 32-40 ILTVILGVL (88)
Tyrosinase A1 243-251 KCDICTDEY (89)
A2 1-9 MLLAVLYCL (90)
A2 369-377 YMNGTMSQV (90)
y m d g tm sqV*) (91)
A24 206-214 AFLPWHRLF (92)
B44 192-200 SEIWRDIDF (93)
TRP-l/gp75 A31 1-9*^ ) MSLQRQFLR") (94)
TRP-2 A31A33 197-205 LLPGGRPYR (95)
Mutated and aberrantly expressed antigens
MUM-r^ B44 nt782-808 EEKLIWLF (96)
P-Catenin A24 29-37 SYLDSGIHF (97)
pl5 A24 AYGLDFYIL (98)
CDK4 A2 ACDPHSGHFV (99)
GnT-V*^ A2 VLPDVFIRC(V) (100)
gpl00-in4A24 170-178
r * T T ---- 1,^ 11 -------
VYFFLPDHL (101)
Natural peptide identified by elution from HLA-A2
Antigenic peptide resulted from translation of an alternative open reading frame (0RF3) of the gp75 gene
Mutation occurs in an intron sequence introducing a stop codon.
N-acetylglucosaminenyltransferase V. The peptide is encoded by an intron sequence.
Several studies have focused on the characterisation of the T-cell response against malignant 
melanoma in situ, and evidence has been provided for the presence of clonally expanded T cells in 
both primary and metastatic lesions (102-108). These data strongly indicate that melanoma cells 
present antigenic peptides in the context of HLA molecules, and that T cells capable of recognising 
these antigens are detectable in situ.
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However, the response is obviously inadequate to control tumor growth, as tumour 
progression often occurs, raising the question of how melanoma cells escape immune surveillance.
One frequently suggested mechanism is that tumor cells lose the expression of MHC class I molecules, 
rendering them invisible to the T cell. Most studies demonstrating loss of expression of class I 
molecules in melanoma have been carried out using histological staining of melanoma lesions. This 
approach is hampered by the low sensitivity of this technique -  at least 200 molecules are required for 
a positive stain and large areas of the tumours are often necrotic. Furthermore, in contrast to these 
findings, very few class I negative melanoma cell lines have been described (109). Therefore other 
mechanisms are more likely to cause the immune escape of melanoma.
It has been suggested that TILs in melanoma and even peripheral T cells from melanoma 
patients have an impaired signaling capacity through the TCR/CD3 complex due to downregulation of 
the CD3 ^-chain (110). The mechanism underlying this downregulation remains elusive.
Melanoma cells are known to secrete a number of different cytokines some of which may 
suppress cellular immune responses e.g. IL-10 (111; 112) and TGFp (113; 114). Normal melanocytes 
are responsive to growth inhibition to TGFp, whereas melanomas are not. In other tumour types 
unresponsiveness to TGFp have been shown to be accomplished by mutations in Smad4/DPC4, a gene 
encoding a protein essential to TGFp mediated intracellular signaling (115-117). However, in the 
analysis of more than 40 melanoma cell lines we detected no Smad4/DPC4 mutations (thor Straten & 
Guldberg, unpublished data). It is possible that unresponsiveness to TGFp in melanoma is achieved by 
deletions or mutations of pi 5.
Another immune escape mechanism likely to be used by melanoma cells is the expression of 
the Fas ligand, implying that T cells that attempt to encounter the melanoma cells may be killed if they 
are susceptible to Fas mediated apoptosis (118; 119).
A number of immunotherapeutic trials have been carried out with the aim of boosting the 
(ongoing) T-cell response. Earlier trials were in most cases conducted by the systemic administration 
of immunomodulatory cytokines such as IL-2 (120). Although some beneficial effects were observed, 
the general results were not encouraging, as the response rates were limited and the side effects severe
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(121). One of the major obstacles is that the systemic administration of cytokines neglects the 
paracrine nature of cytokines. This limitation has been overcome in a murine tumor model by the use 
of targeted IL-2 therapy using a fusion protein consisting of a tumor-specific antibody and IL-2 (122; 
123). Using targeted IL-2 therapy it has been shown that established métastasés could be eradicated in 
a response mediated by CDS T cells (122). Furthermore, it was recently shown that tumor eradication 
is presumably accomplished by the activation of T cell clones present in the tumor lesion prior to 
therapy (124). However, this therapeutic model has not yet been tested in humans. Another approach, 
which has been used in a clinical setting, is the adoptive transfer of autologous in vitro expanded 
lymphokine activated killer (LAK) cells or TEL; either alone or in combination with IL-2 (125). The 
objective responses have been limited.
Discovery of tumor regression antigens and the resulting peptides has prompted peptide based 
vaccination trials. Immunisation of HLA-A2 positive melanoma patients have been carried out using 
subcutaneous injections of peptides derived from MART-1, gplOO and tyrosinase. However, no tumor 
regressions were observed (126). Likewise the subcutaneous injection of the MAGE-3/HLA-A1 
peptide only revealed minor responses (127). Very recently, two different vaccination trials were 
conducted using DCs pulsed with tumor lysates or peptides. The results were impressive showing 
partial or complete regression in more than 40% of the patients (128; 129). Whether these promising 
results will stand the test of more extensive randomised trials remains to be established.
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Scientific Results
Aims of the study
The primary aim of the present study has been to investigate the role of T cells infiltrating human 
melanoma, with specific focus on the analysis of in situ T cells. Most studies of TIL in melanoma have 
been concerned with melanoma cell lines and in vitro propagated TIL. These investigations have 
revealed important new insight into the MAA expressed by melanoma cells and the T-cell recognition 
of these, as summarised on the preceding pages. These in vitro findings have made it plain that the 
biological foundation in terms of a T-cell response against melanoma was not unsound. However, it 
also made clear that the in vitro situation was markedly différent fi-om the in vivo situation. In contrast 
to the in vitro cytotoxicity data against well-characterised MAA, the in vivo T-cell response is 
obviously insufficient to clear tumour burden. To get a glimpse of what goes on in situ, we have aimed 
at investigating melanoma lesions for the presence of clonotypic T cells.
The present Thesis is introduced with a discussion of reverse transcription polymerase chain 
reaction (RT-PCR) based analysis of TCRBV regions, including the description of a panel of primers. 
Using this primer panel, we analysed for TCR clonality in progressive versus regressive parts of 
partially regressive primary melanoma lesions (paper 1). The main conclusion drawn fi’om this study 
is that clonotypic T cells were present in both regressive and progressive parts of the same lesions. 
However, sequencing of “non clonal” BV-regions demonstrated that most of them were not polyclonal 
by nature but oligoclonal e.g. that in some cases all transcripts were of the same length or only a 
limited number of BJ regions were used. This indicated that some T-cell clones were left undetected 
by direct sequencing.
To facilitate full and detailed analysis of T-cell clonotypes in the infiltrates we aimed at 
establishing a suitable method for the detection of clonally expanded T cells. Denaturing gradient gel 
electrophoresis (DGGE) was chosen because this method is highly sensitive and excludes laborious 
steps that are obligatory in almost all other methods dealing with the detection of TCR clonality (paper 
2).
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We applied the DGGE based method to analyse for in situ T-cell clonality in 6 subcutaneous 
melanoma lesions from two patients. The results demonstrated two important characteristics of in situ 
TIL in melanoma. First, the infiltrate constitutes an exceedingly high number of different T-cell 
clones, and second, the T-cell response appears to be executed by local T cells that do not enter the 
periphery (paper 3).
The final study deals with a comparative analysis of in situ T cells and T cells propagated in 
vitro, demonstrating that standard in vitro culture conditions do not support the growth of in vivo 
expanded T-cell clones (paper 4).
19
RT-PCR based analysis of T-cell receptor variable regions pi-24 
Abstract
The present report describes a series of oligonucleotide primers specific for TCR variable regions.
The primer panel consists of 5' primers covering the TCRBV regions 1-24 and a 3'primer matching to 
the TCRBC regions. Primers were selected for best possible match to the relevant TCRBV families 
and a minimum of 5 mismatches to all other families.
By using the computer program Oligo 3.4, primers were chosen to produce PCR products 
within a limited size range, to have a minimum of internal secondary structures and primer dimers, to 
have similar melting temperatures (Tm) and AG values, and to work using standardised conditions.
The specificity and efficiency of the primer panel were tested in reverse transcription polymerase 
chain reaction (RT-PCR).
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Introduction
The polymerase chain reaction has been the method of choice in most laboratories aiming at analysing 
for the expression of TCRBV regions. Although several different PCR based methods for that purpose 
have been described, the most commonly used has been reverse transcription polymerase chain 
reaction (RT-PCR), in which TCR transcripts is amplified with a set of primers covering the variable 
region famihes, together with a common constant region primer.
For the purpose of analysing T-cell infiltrates in malignant melanoma, RT-PCR was chosen 
because of its capacity to analyse minute amounts of material and its ability to produce 
semiquantitative data. Furthermore, using PCR based methods it is possible to proceed directly 
through steps of cloning or sequencing. However, the validity of semiquantitative RT-PCR is highly 
dependent on parameters such as primer stability in duplex formation, specificity and discrimination of 
non-targets. Furthermore, it is imperative that all reactions work well and are being carried out within 
the linear range of amplification.
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Materials and Methods.
Selection of primer sequences
The primers for amplification of BV regions 1-24 were carefully selected with the aim of perfect 
match to the BV family in question and all sub-members of the femily. Sequences of TCRBV regions 
were obtained firom the GenBank Database using the accession numbers given by Arden et al. (23). 
Sequences not available in the GenBank Database were typed in by hand. Library files were created 
for each TCRBV family using the PC/GENE “FILE” program (Intelligenetics, Palo Alto, CA, USA). 
Using the PC/GENE program “CLUSTAL”, the sequences in each family were aUgned, and primer 
sequences were found in regions of optimal consensus. Optimal primer sequences were found using 
the computer program Oligo Version 3.4 (Medprobe, Oslo, Norway) (130) aiming at AG below -40.0 
and a Tm between 50°C - 60°C. The BV primers BVl, BVIO, BVl 1 and BV22 have been described 
(131). All primers were subsequently tested for potential homology to all other families, aiming at a 
minimum of 5 mismatches to non-relevant BV templates. Most of the primers used in this study meet 
these criteria although in some families it was not possible to achieve 100% match to all subfamily 
members using a single primer. For that reason some BV families are covered by two primers (BV12 
and BVl 3), or by the use of mixed base positions in the primer (BV5 and BV6). In other instances 
mismatches to some BV subfamily members were accepted in the 5 '-end of the primer. The sequences 
of the primers, numbered according to Arden et al. (23), are given in Table 3.
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T a b l e  3  O l i g o n u c l e o t i d e  p r i m e r s  f o r  t h e  h u m a n  T C R B V  f a m i l i e s .
BV Sequoice Pos Size AG Tm
BVl 5'-CCGCACAACAGTTCCCTGACTIXjC-3’ -92 456 -47.5 63.5
BV2 5 'TCTCATGCTGATGGCAACTTCCAAT 3' 163 527 -46.5 60.6
BV3 5'-CGdTCTCCCTGATTCTGGAGTCC-3' -66 430 ^7.1 61.2
BV4 5'-TTCCCATCAGCCGCCCAAACCTA-3' -92 456 -49.9 65.0
BV5 5-CTGAG OaTGAATGTGA AJqC G/aCCTTG-3'' -60 424 -42.0 56.0
BV6 5’-MAGRATGTARMKCTCAGGTGTGAT-3’ -135 582 -40.0 50.0
BV7 5'-TAAGAAGTCTTTGAAATGTGAACAAC-3 ' -221 585 -47.2 62.0
BV8 5-TGAAGATCCAGCCCTCAGAACCC-3' -56 420 -45.3 60.2
BV9 5'-AACAGGACTCTAAGAAATTTCTGAAG-3' -175 539 -42.5 49.4
BVIO 5-CCACGGAGTCAGGGGACACAGCAC-3' -43 407 -47.8 65.5
BVll 5'-TGCCAGGCCCTCACATACCTCTCA-3' -43 407 -47.4 63.5
BV12 5'-GAGAAnTCCTCCTCACTCTGG-3' -70 434 -39.2 51.2
5-GACCTCCCCCTCACTCTGG-3' -70 434 -37.8 53.0
BV13 5-CACTGAGATGTACCCAGGATATGA-3' -220 584 -40.2 52.4
5-TGCAGTGTGCCCAGGATATGA-3' -217 581 -39.8 56.2
BV14 5'-GGGCTGGGCTTAAGGCAGATCTAC-3' -165 529 -$8.2 60.3
BVl 5 5*-CAGGCACAGGCTAAATTCTCC-3' -79 443 -40.2 53.1
BV16 5'-GATGAGTCCGGTATGCCCAACAATC-3' -117 481 -47.8 61.3
BV17 5:-CCCCAAAGTACCTGTTCAGAAA-3' -263 627 -40.4 52.6
BVl 8 S'-TTrCTGCTGAATTTCCCAAAGAGG-S' -91 455 -45.7 57.7
BV19 5-TCTCAATGCCCCAAGAACGCAC-3 ' -87 451 -44.5 60.8
BV20 5'-AGGTGCCCCAGAATCTCTCAG-3' -105 469 -40.3 54.7
BV21 5-GAYGATICACAGTTGCCTAAGGA-3' -119 483 ^1.5 53.8
BV22 5'-AAGTGATCTTGCGCTGTGTCCCCA-3’ -234 598 -47.4 63.5
BV23 5'-GCAGGGTCCAGGTCAGGACCCCCA-3' -172 536 -42.4 60.3
BV24 5'-ATCCAGGAGGCCGAACACTTC-3' -87 451 -42.0 56.8
BCseq2 5-ACAGCGACCTCGGGTGGGAA-3' 97 -43.4 61.2
BC4 5 -CGTAGAACTGGACTTGACAGCGG-3 ' 304 -43.3 57.7
BC-5’ 5’-ÏGAGC1GG IXKjG1XjAA1XjGG-3' 187 343 -40.5 57.9
BC-3' 5-GGTGGCCTTCCCTAGCAGG-3' 530 -40.7 55.9
Position +1 is defined as die first nucleotide after the sequence coding for the conserved amino acid sequence CASS in the 
proximal end of the variable domain. The approximate sizes of the PCR products are calculated using an estimated mean 
length of die DJ region of 60 bp.
Isolation of RNA and synthesis of cDNA
RNA was extracted by a modification of the method described by Chomczynski and Sacchi (67; 132). 
cDNA synthesis was performed according to the manufacturer's protocol using M-MLV reverse 
transcriptase (Life Technologies Inc., Gaithersburg, MD, USA) primed with oligo-dT. Incubations 
were perfonned at 42°C for 30 min, 99°C for 5 min. and frozen or used immediately,
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RT-PCR conditions and parameters
Several different PCR parameters were tested with specific focus on annealing temperature (55®C, 58°C, 
60°C, 62°C and 65°C). Several primers gave rise to spurious amphfication products at an annealing 
temperature of 55°C and 58°C, and some primers were inefficient at an annealing temperature of 62°C 
(data not shown). At 60°C, most primers worked well although some unspecific amplifications were 
identified. To further increase specificity, “touch down” (133) and “hot start” (134) cycling parameters 
were introduced. These stratagems, in particular the “hot start”, increased specificity while leaving 
efficiency unaffected (data not shown). The parameters used for amplification were 94°C for 30 sec, 
60°C for 30 sec. and 72°C for 60 sec., using “touch down” going fix>m 65°C to 60°C over the first 10 
cycles. Taq polymerase and dNTPs were added to the reaction tube at an 80®C step between die 
dénaturation and annealing steps of the first cycle.
In addition to annealing temperature other reaction conditions affecting the specificity and 
sensitivity were tested. These experiments included changes in primer and nucleotide concentrations, Taq 
polymerase fi-om different manufacturers and different concentrations of enzyme. Eventually, 
amplifications were carried out in 50mM KCl, 20 mM Tris pH 8.4,2.0 mM MgCl2 , 0.2 mM cresol red, 
12% sucrose, 0.005% (w/v) BSA (Boehringer-Mannheim, Mannheim, Germany)) using 2.5 pmol of 
each primer, 40 pM dNTPs (Pharmacia LKB, Uppsala, Sweden) and 1.25 units of AmpliTaq 
polymerase (Perkin Elmer Cetus Corporation, Emeryville, CA.). The inclusion of cresol red and 
sucrose in the reaction buffer enables direct loading to the gel (135).
Semiquantitative RT-PCR
For quantitative analysis either Southern blot analysis was carried out as described (136), or the BC 
primer was labeled with ^^ P, ahqouts electrophoresed in an agarose gel, and the gel dried prior to 
exposure to Molecular Dynamics Storage Phosphor Screen (Molecular Dynamics, Sunnyvale, CA, 
USA). In either case quantitation was accomplished using the Imagequant software (137).
To validate the semiquantitative RT-PCR methodology, serially diluted cDNA was PCR 
amplified for different numbers of cycles (26,28, 30, 32, and 34) using the primers BV 1-24 together
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with the constant region primer BC4. Data from these experiments were used to determine the amount 
of cDNA and the number of cycles through which the specific PCR products accumulated 
exponentially, enabling determination of the relative abundance of each TCRBV region. Furthermore, 
the accuracy and reproducibility of the method were investigated by repeated analyses of peripheral 
blood lymphocytes (PBL) indicating that the experimental variation represented 4-8% of the mean 
value. The primers BC-5 ' and BC-3 ', matching to TCRBC exons 1 and 3 respectively, were used to 
amplify all TCR cDNAs in each sample. The amount of TCRBC PCR product was quantitated using 
Imagequant software (137), ensuring that all TCRBV analyses were carried out using equal amounts of 
TCRcDNA.
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Results and Discussion
Since the PCR methodology was first described in 1985 (138) and later in 1987 using a thermostable 
Taq polymerase (139) it has become one of the most widely used techniques in scientific research. 
Initially, PCR was not viewed as a quantitative method, but the ability to analyse small amounts of 
nucleic acids thereby enabling quantitative analysis to be carried out in situations where RNA amounts 
were too small for conventional Northern blotting, were too obvious to be overlooked. For the analysis 
of multigene families such as the TCR, the field opened with the paper of Choi et al. in 1989 (140) and 
since then quantitative PCR of TCR variable regions have been conducted in many laboratories.
A major obstacle in semiquantitative RT-PCR based analyses of multigene families is to 
select primers that work equally well and do not crossreact within the different families. Since the first 
primer panels for TCR cx/p chaiiw were published almost a decade ago, the full genomic DNA 
sequences of TCRAB regions have been published (24; 25), and the classification of different BV/AV 
sequences into the relevant families has recently been updated (23). Obviously, primer panels for the 
amplification of multigene famihes must be updated according to available sequence data in order to 
ensure that all members of the different families are amplified. For this purpose, the publication of all 
TCRV sequences has greatly aided the selection of specific primers. The vast majority of the 
previously published primer panels either do not match optimally to all sub-members of the different 
families, or show potential crossreactivity to other famihes (140-146). Actually, with regards to 
crossreactivity only a single primer panel has been published for which this topic has been included in 
the selection of the primer sequences, although with the more recent updates of sequence data not all 
primers match optimally to the target sequences (131).
In the present study, TCRBV sequences were put into hbrary files according to the BV family 
and aligned to find sequence stretches of optimal consensus in which primer sequences could be 
selected. All primer sequences were tested for match to non-relevant BV famihes aiming at a minimum 
of 5 mismatches. Most importantly, however, primers were tested for the ability to amplify the BV 
region in question with high efficiency. During the optimisation steps of the PCR parameters and 
conditions, several primers were changed in order to have a panel of primers that worked equally well.
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with high sensitivity, stability and efficiency. Fig. 5 depicts RT-PCR products of TCRBV regions 1-24 
electrophoresed in agarose and stained with ethidium bromide (EtBr).
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Figure 5. RT-PCR amplification products of TCRBVl-24 transcripts in peripheral blood lymphocytes 
of healthy donOrs. Visualised by staining with EtBr.
For semiquantitative analysis using RT-PCR many researchers take advantage of co­
amplification of a control TCR a-constant chain PCR product in each tube, in order to equalise for any 
differences in the amount of target or other tube to tube differences. In the present study, several 
experiments were conducted, demonstrating that the amplification efficiency of two different targets in 
the same tube did not always reflect each other. In other words, the efficient amplification of one of the 
targets in the tube does not necessarily imply that the other target is amplified equally efficiently (147). 
Furthermore, it became clear that “duplex” amplifications in many situations decrease the amplification 
efficiency of both targets and increase the risk of spurious amplification products. Consequently, 
semiquantitative analysis of TCRBV regions in the present study has been carried out without co­
amplification. All reactions are prepared as master reaction mixtures containing all reagents except the 
BV primer, and master mixture aliquoting is being conducted with high precision.
Nevertheless,.semiquantitative PCR has its limitations. Preliminary experiments were 
conducted to show that the amount of cDNA used would amplify all 24 TCRBV regions exponentially 
when PBL cDNA was amplified. In general the probable error represented 4-8% of the mean value in 
duplicate experiments. However, the experimental variation may reach higher values both at very low 
and at very high concentrations of target. At very low signal strengths the background values may 
constitute a relatively high proportion of the signal, even with highly sensible detection systems such as
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the Phosphor Imager. This means that small changes in the background values over the gel, and from 
one gel to another, may induce significant differences even when the same sample is run in different 
gels. It is therefore not possible to make valid distinctions between different values below 2%.
At very high target concentrations the increased error rate is related to the nature of PCR. 
When a single BV region constitutes close to the majority of the T-cell population, the present setup 
will not ensure that all reactions stay within the exponential phase of the reaction. For that reason, the 
PCR amplification of TCR transcripts expressed at extremely high levels, will reach the “plateau 
phase” and consequently be underestimated with regards to the level of expression. In PBL cDNA the 
relative abundance of the different BV regions is normally in the range of 2-12 %, meaning that none of 
the TCRBV regions dominates the pool of TCR messengers. This may not be the situation when 
different T-cell infiltrates are analysed in which single BV regions may constitute the majority of the 
infiltrate (136). However, with the relation between the number of cycles and the amount of cDNA 
used in the present study, reasonable estimation of BV region expression can be made even when single 
BV regions constitute up to approximately 30% of the TCR messenger pool (136).
These considerations clearly illustrates that any setup of semiquantitative RT-PCR based 
analysis of multigene families necessarily will be a compromise of being able to detect and quantitate 
targets expressed at very different levels. Possibly one of the major pitfalls in semiquantitative PCR 
therefore is related to the understanding of these limitations in the evaluation of the data.
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Clonal T-cell responses in tumour infiltrating lymphocytes from regressive 
and progressive regions of primary human melanoma
Abstract
The TCRBV region repertoires of TEL from progressive and regressive parts of the same primary 
human melanoma lesions were characterised by RT-PCR. After surgery, the tumours were divided 
into different parts that were judged as regressive or progressive regions by visual inspection. 
Subsequently this diagnosis was confirmed by histology. From a total of 4 primary melanomas 
analysed, 2 were shown to be HLA-A2\
Only relatively few BV-region families were expressed at significant levels in each of the 
samples. Comparison of the BV-region expression in regressive versus progressive regions of the 
same tumour revealed major differences in all cases examined. Direct sequencing of RT-PCR products 
indicated that highly expressed BV-regions of clonal origin were present in both regressive and 
progressive regions.
Together, these data strongly suggest the occurrence of clonal T-cell responses in both 
regressive and progressive areas of the same primary tumour. The differences in expression of certain 
BV-regions may correlate with the functional activity of certain populations of tumour-infiltrating T 
cells.
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Introduction
The prognosis of melanoma, which cannot be cured by surgical resection, is one of the most 
unfavourable in medicine. The coexistence of tumour specific immunity with a progressing tumour 
remains a major paradox of tumour immunology. This enigma is most evident in partially regressing 
melanoma, where efficient eradication of tumour cells occurs in close vicinity to uncontrolled tumour 
growth. Everson and Cole (148) have defined spontaneous regression of malignant melanoma as the 
partial or complete disappearance of a malignant tumour in the absence of all treatment. Such 
spontaneous regressions of primary cutaneous melanoma are not uncommon and are clinically 
manifested by a decrease in the amount of pigmentation, variation in colour, scarring and division of 
the original lesion into multiple smaller lesions.
The usage of TCRBV region repertoires of TIL in primary human melanomas has recently 
been characterised indicating the presence of clonally expanded T cells in the tumour (102; 149; 150). 
However, all studies thus far have analysed the TCR V-region repertoire in the total tumour sample. 
The occurrence of spontaneous regression of primary melanoma is correlated with a high degree of 
lymphocyte infiltration (55). Therefore, it is possible that clonal T-cell responses may originate 
exclusively jfrom the regressive parts of the tumour.
To test this notion, TCRBV region repertoires in regressive versus progressive regions of 
different primary melanomas were analysed by RT-PCR. Only very few BV-gene families were 
expressed at high levels with major differences in regressive versus progressive regions of the same 
tumour. Highly expressed BV-regions of clonal origin were found in both regressive and progressive 
parts of the same tumour, suggesting a clonal T-cell response to occur in both parts of malignant 
melanoma primary tumours.
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Materials and Methods
Tumour samples
Fresh primary melanoma lesions were received as biopsy material immediately after surgery performed 
at the Department of Dermatology, School of Medicine, Würzburg. Four patients were included in this 
study. The tumours were examined for Clark level, type, localisation and thickness. The tumours were 
separated into progressive and regressive regions by visual inspection that was subsequently validated 
by histological analysis (151).
Isolation of RNA and synthesis of cDNA
RNA was extracted by a modification of the method described by Chomczynski and Sacchi (67; 132). 
cDNA synthesis was performed according to the manufacturers' protocol using M-MLV reverse 
transcriptase (Life Technologies Inc., Gaithersburg, MD, USA). Incubations were performed at 42°C 
for 30 min, 99°C for 5 min. and fi-ozen or used immediately.
In order to analyse equal amounts of TCR cDNA fi-om each sample, different cDNA dilutions 
were amplified by PCR with primers for the constant region of the B-chain (Primers BC-5 ' and BC-3 '
1. PCR amplification; 20 cycles, reamplification; 35 cycles). The amounts of cDNA to be used for the 
BV-analyses was determined on the basis of the intensity of these PCR-products observed after agarose 
gel electrophoresis and subsequent staining with EtBr.
TCRBV PCR
In the present study we analysed for the expression of TCRBV regions using 24 primers covering the 
BV regions 1-24 in conjunction with a common BC primer (136). Since the amount of cDNA was 
limited, each analysis was performed initially with 20 cycles using BC4 as 3 '-primer. Aliquots fi-om 
this first amplification were diluted 1/100 and 5 p,l of this sample were amplified by further 35 cycles 
of PCR using a nested 3'-primer (BCseq2, Table 3). Reactions were carried out as described (136), 
with the exception that in the reamplification reaction, the primer concentration was raised fi-om 1,25 to 
5 pmol and the dNTP concentration was raised fi-om 10 to 40 pM.
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Cross contamination was avoided by use of plugged pipette tips (Mplti Technology Inc. Salt 
Lake City, Utah, USA) and separate rooms for pre- and post-PCR handling. Negative controls were 
samples without cDNA. All amplifications were performed in a Hybaid Omnigene Thermal Cycler 
(Ilybaid, Teddington, Middlesex, UK) using standard microtubcs (Mplti Technology Inc., Salt Lake 
City, Utah, USA). For analysis, 15 pi aliquots of PCR products were subjected to electrophoresis in a 
3% NuSieve 3:1 agarose gel (FMC BioProducts, Rockland, ME) for 3 hours at 100 V.
HLA-A2PCR
Analysis ofHLA-A2^ mRNA expression was performed by RT-PCR. The parameters were as 
described above with the exception that the "touch down" were carried out fi-om 70°C to 62°C. Two 
different HLA-A2 samples were analysed as negative controls. Primers used were 5 -GGGACGGG 
GAGACACGGAAA-3' (sense) and (5 '-AGCGGATCCAGTCATATGCGTTTTGGGGGC-3 ' 
(antisense) taken firom published HLA-A2 cDNA nucleotide sequence (152). The underlined sequence 
corresponds to an added Bam-Hl site. The resulting PCR product consists of 390 bp.
Southern Blots
After electrophoresis, PCR products were transferred to nylon membranes and hybridised as previously 
described (136). 1/1 mixtures of P^  ^labelled oligonucleotides, BHYBl (5'-
AACACCTTGTTCAGGTC-3') and BHYB2 (5'-AACACGTTTTT CAGGTC-3'), which match BCl 
and BC2, respectively, were used as probes. After washing, the radioactive probes were visualised 
using a Molecular Dynamics Storage Phosphor Phosphoimager (137).
Sequence analysis
Highly expressed BV-regions were sequenced in order to investigate the clonality of their expression. 
After re-amplification, the PCR products were extracted fi-om agarose gel, precipitated with ethanol and 
resuspended in 10 pi IXPCR buffer (Perkin Elmer Cetus, Emeryville, CA). Sequenase version 2.0 
(USB Corporation, Cleveland, OH, USA) was used following the manufacturers' suggestions.
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However, in order to sequence directly, we used a labelled primer (CPseq2) and dénaturation was 
carried out by boiling for 5 min in a total volume of 12 pi. The gels were analysed with a Molecular 
Dynamics Phosphoimager.
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Results
Histopathology
The histopathological characteristics of the tumour samples are given in Table 4.
Table 4. HLA-A2 expression and histopathological characteristics of the tumour samples.
Tumour HLA-A2 Localisation Type* Thickness Clark le
1 - Trunk NMM 1,5mm V
2 + Arm SSM 1,4mm IV
3 - Leg SSM 1,8mm IV
4 + Trunk SSM 1,9mm IV
*SSM: superficial spreading melanoma; NM: nodular melanoma
TCRBV 1-24 expression
RT-PCR was used to compare the TCRBV repertoire of TIL infiltrating regressive and progressive 
parts of 4 primary melanoma tumours. Each amphfied RT-PCR product was obtained with the expected 
size as a single band in all cases, A limited number of BV-regions were expressed at significant levels 
in each sample. The number of different BV-regions expressed at significant levels in each
Table 5. TCRBV expression and clonality in the tumour samples.
Tumour 1 progressive BV4*, BV5*, BVSf, BV13*
Tumour 1 regressive BV3*, BV5, BVl 3*, BVl 8
Tumour 2 progressive BV4*, BV12, BV14
Tumour 2 regressive BV2*, BV4, BV12, BV20*
Tumour 3 progressive BV13*, BV14*, BV20
Tumour 3 regressive BV6*, BV13, BV21*, BV24*
Tumour 4 progressive BV3, BV5, BV14*, BV15f, BV17f
Tumour 4 regressive B V r, BV3Î, BV5, BV7, BV13J, BV15,
TCRBV-regions expressed in progressive md regressive parts of the tumour samples. *, regions 
shown by sequence analysis to be of clonal origin. J, regions not sequenced.
34
tumour ranged from 7-11. In general, the regions BV3, BV4, BV5, BVl3, BV14 and BV20 were 
expressed in more than one tumour, whereas the regions BVl, BV2, BV6, BV7, BV8, BVl2, BVl5, 
BV17, BV18, BV21 and BV24 were expressed in one tumour only (Table 5).
In no instance had the regressive/progressive parts of the same tumour a similar pattern of 
BV gene expression. For example, both patients 1 and 4 show expression of BV3, BV5 and BVl3. 
However, regions BVl, BV4, BV7, BV14, BV15 and BV17 are expressed exclusively in one of the 
tumours. Some BV regions were not expressed in any of the tumours, including BV9, BVIO, BVl 1, 
BV16, BV19, BV22 and BV23. Comparing the expression of specific TCRBV in the different areas of 
the tumour in all cases showed major differences. Examples of this phenomenon are the expression of 
BVl 8 which is highly expressed in sample 1 progressive (prog.) and absent in sample 1 regressive 
(reg.); BVl in tumour 4 reg. but absent in tumour 4 prog, and BV14 present in tumour 4 prog, but not 
in tumour 4 reg. (Fig 6), and BV20, which is highly expressed in tumour 2 reg. but absent in tumour 2 
prog. However, in all tumours analysed one or a few regions were expressed in both parts of the 
tumour (Table 5)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Wi
Figure 6. Southern Blot analysis of PCR amplification products of TCRBV regions 1-24 in biopsy 
material from tumour 4; upper, regressive part; lower, progressive part.
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HLA-A2 RT-PCR
The expression of HLA-A2 was examined with specific primers for HLA-A2 and RT-PCR under 
highly stringent conditions. The results showed correctly sized PCR products derived fi-om the 
amplification of cDNA fi-om tumours 2 and 4 (Table 4)
Sequence analysis
Several BV-regions were sequenced in order to investigate whether any of these regions were of clonal 
origin. From a total of 28 PCR products sequenced, 14 of these revealed distinct CDR3 regions, all 
showing the expected BV-region sequence (Table 6). Readable CDR3 sequences were found in both 
regressive and progressive parts of the same tumours. In the samples 1 reg./l prog., both the regressive 
and the progressive regions of this tumour showed expression of BVl 3. The sequence analysis in both 
cases showed a readable CDR3 region; however the sequences were different. In tumour 4, both parts 
of the tumour showed a readable CDR3 region (BV14 and BVl, respectively). However, the BV5 
region expressed in both parts of this tumour showed a non-readable CDR3 region. Table 6 depicts the 
nucleotide sequence as well as the deduced amino acid sequence from those sequences showing a 
readable CDR3.
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Discussion
Melanoma lesions in many cases show clear signs of regression in some parts whereas other parts of 
the same tumour show progression (66). Therefore it is possible that progressive samples or progressive 
parts of the tumours would not give rise to specific HLA-restricted T-cell responses, as two known 
tumour escape mechanisms are loss of HLA or antigen (153-155). If this is the case, it should not be 
possible to detect clonal T-cell responses in these parts of the tumours.
Here, we have attempted to answer this question by analysing progressive and regressive 
parts of four primary tumours. Our data clearly indicate that clonal T-cell expansions take place in both 
regressive and progressive regions of the tumour and that the T-cell responses directed against the 
progressive and regressive parts are strikingly different. Recent studies have shown major dififerences 
in the BV-expression of TILs when primary tumours were compared with metastatic tumours (108). In 
the present study, we demonstrate that these differences might actually be present in the primary 
tumour but become apparent only when different parts of the tumour are analysed separately. In fact, 
although in some cases the same BV-regions are expressed in both parts of the tumour (i.e. BVl 3 in 
tumour 1, BV5 tumour 4) sequence analysis of the CDR3 region showed that they are not derived fi*om 
the same monoclonal T-cell expansion.
Several explanations can be put forward to account for these marked discrepancies. The 
differences in BV-region expression may be the result of different antigens expressed on tumour cells 
present in regressive versus progressive areas. However, it should be noted that different TCR 
rearrangements are able to react with the same MHC/peptide complex (85; 156; 157). Nevertheless, 
Sensi and colleagues (158) reported that the majority of cytotoxic T-cell clones recognising MART- 
1/Melan-A in the context ofHLA-A2^ use TCRBV7 or TCRBV14. Recently, this was followed by an 
analysis of TCRBV in HLA-A2^ primary tumours showing that TCRBV14 was highly expressed in all 
tumours examined (150). Taken together, these data indicate that although different TCRs may 
recognise the same HLA/peptide complex, there is strong selection of receptors carrying certain 
TCRAV/BV chains. In the present study, TEL in three out of four tumours, including two which were 
HLA-A2^ (tumours 2 and 4), showed expression of TCRBV14. TEL of tumour 4 showed expression of
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BV7 in the regressive part and BV14 in the progressive part. In addition, TEL of tumour 2 showed a 
clonal expansion of TCRBV4, which similarly to TCRBV14 was capable of recognising MART- 
1/Melan-A in the context of HLA-A2 (158). Thus, it is probable that some of the TCRBV-regions 
found to be expressed in the present study may recognise antigenic peptides derived from the MART- 
1/Melan-A protein. This conclusion is supported by the fact that practically all melanomas express this 
protein (109; 150). It is therefore possible that future studies of TCR usage in HLA typed melanoma 
lesions may provide further information about the antigens giving rise to the major T-cell responses 
against melanoma (104).
Although this study is limited to four tumours, the data suggest that T-cell responses may be 
directed against both regressive and progressive tumour cells. If this is the case, it is likely that HLA or 
antigen losses are not the major tumour escape mechanism for malignant melanoma. In this regard, it is 
notable that rather few melanoma cell lines are negative for HLA-expression. We recently analysed 20 
melanoma cell lines from 20 HLA-A2^ patients and found only one of them to be HLA-A2 negative 
(by FACS and RT-PCR) (109). Ferrone et al. (154) suggested the loss of expression of genes involved 
in transport or processing of the antigen for presentation with HLA class I as a tumour escape 
mechanism. In this context, we have analysed a large panel of melanoma cell lines for the expression of 
transcripts coding for TAPI and 2 as well as LMP2 and 7. In this rather large material, we did not 
detect any loss of expression for any of these proteins (109). Therefore, this appears to be a highly 
uncommon mechanism for tumour immune escape in melanoma. Thus, the important question why T 
cells seemingly capable of rejecting the tumour fail to do so remains elusive.
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Detection and characterisation of ag T-cell clonality by denaturing gradient 
gel electrophoresis (DGGE) 
Abstract
Accumulation of T cells carrying identical TCR is associated with a number of immunological and 
non-immunological diseases. It is therefore of interest to be able to analyse complex T-cell 
populations for the presence of clonally expanded subpopulations. Here a simple method is described, 
combining RT-PCR and denaturing gradient gel electrophoresis (DGGE) for rapid detection and 
characterisation of T-cell clonality. The detection of clonally expanded T cells by DGGE relies on the 
fact that clonal transcripts have no junctional diversity and therefore resolve at a fixed position in the 
gel, determined by their melting properties. For polyclonal populations with a high degree of 
junctional diversity, the different DNA molecules will resolve at different positions in the gel and 
together will be revealed as a smear. For each of the TCR families BVl-24, cloned transcripts were 
amplified and shown to resolve as distinct bands in the denaturing gradient gel, whereas the analysis 
of polyclonal T-cell populations resulted in a smear.
The present method may prove useful to test for clonotypic T cells in a variety of pathological 
and physiological conditions, and for monitoring T-cell responses in diagnostic and therapeutic 
settings.
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Introduction
A number of different methods exist for the detection of T-cell clonality. The most widely used 
methods are based on RT-PCR followed by single strand conformation polymorphism (SSCP)(159), 
PCR heteroduplex analysis (160) or CDR3 size determination (161). However, all these methods 
require steps of either blotting and hybridisation or reamplification using end-labeled probes followed 
by computerised data analysis. In the present study, we have developed a method based on RT-PCR 
and denaturing gradient gel electrophoresis (DGGE) to rapidly screen for the presence of clonal T cells. 
The method detects the presence of T-cell clonotypes, covering the BV regions 1-24, and facilitates the 
possibility to produce full and detailed ‘TCR clonotype maps”.
DGGE is a powerful method for the detection of small deletions, small insertions and point 
mutations, having detection efficiency close to 100% (162). The method relies on the fact that the 
melting properties of a DNA molecule are highly dependent on the nucleotide composition. During 
electrophoresis in a denaturing gradient gel, the DNA molecule will partially melt at a sequence- 
dependent concentration of dénaturants, and the resulting partial separation of the DNA duplex will 
retard the molecule and thereby reveal a distinct band in the gel. This imphes that even single base pair 
changes in a DNA sequence can be revealed in a denaturing gradient gel by a shift in the position at 
which the molecule is retarded (162). In a polyclonal T-cell population, all TCR DNA sequences will, 
in theory, differ fi-om each other in their melting properties and will therefore be revealed as a smear in 
the denaturing gradient gel. In contrast, any population of clonally expanded T cells will be revealed as 
a distinct band which can be recovered for further analysis.
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Materials and methods
In vitro culture of peripheral blood lymphocytes
Samples of heparinised blood were obtained from healthy volunteers. Lymphocytes were separated by 
centniiigation on Lymphoprep (Nycomed, Oslo, Norway) and cultured in RPMI-1640 containing 10% 
FCS for four days in the presence of 20 pg/ml phytohemagglutin-P (PHA) (Sigma, ST. Lous. MO, 
USA) for polyclonal stimulation, or 25 pg/ml purified protein derivative (PPD) (Statens Seruminstitut, 
Copenhagen, Denmark) for specific stimulation. Cells were stored as a pellet at -80°C, or RNA was 
isolated immediately.
Primer sequences and melting maps
The sequences of the primers used for the amplification of TCRBV regions 1-24 are given in Table 7. 
Sequences of TCRBV regions were obtained from the GenBank Database using accession numbers 
given by Arden et al. (23). Using the PC/GENE program “CLUSTAL” (Intelligenetics, Palo Alto, CA, 
USA) the sequences in each family were aligned, and primer sequences were found in regions of 
optimal consensus. The selection of optimal primers were aided by the computer program Oligo, 
Version 3.4 (Medprobe, Oslo, Norway) (130), aiming at a AG value of approximately -40.0 and a T^ 
between 50°C and 60°C. Melting maps for amplified PCR products were calculated using the computer 
algorithm MELT87 (163).
RT-PCR
RNA was extracted using the Purescript Isolation Kit (Centra Systems Inc. NC, USA). cDNA synthesis 
was carried out using 1-3 pg of total RNA as described (60). TCR cDNA was quantitated using primers 
specific for the constant part of the P chain (BC5 'and BC3 ') as described (136). Using the same 
amount of TCR template in each amplification, cDNA was amplified using primers specific for 
TCRBV regions 1-24 together with the “GC-clamped” constant region primer BCseq2. Amplifications 
were carried out in a total volume of 25 pi as described (136).
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DGGE
Gels for DGGE analysis contained 6% polyacrylamide and a gradient of urea and formamide from 20% 
to 80%, and were run at 160 V for 4.5 h in Ix TAE buffer kept at a constant temperature of 58°C. After 
electrophoresis, the gel was stained with ethidium bromide and photographed under UV 
transillumination.
In order to demonstrate that all products could be resolved in the gel, PCR products for 
TCRBV 1-24 were cloned using the TA-cloning kit (frivitrogen, San Diego, CA, USA) following the 
manufacturer’s instructions. Positive bacterial clones were PCR amphfred for 30 cycles with the 
specific BV-primer together with the “GC-clamped” BC primer, and 10 pi ahquots were loaded onto 
the gel.
Quantitation of clonotypic transcripts
To investigate the detection sensitivity of the method, PCR was carried out using a ^^ P labeled BCseq2- 
GC primer amplifying PBL cDNA intermixed in different ratios with a clonal TCR transcript (BV17). 
Samples were loaded twice onto a denaturing gradient gel; the second loading was performed 30 min 
before the running time expired, enabling quantitation of the amount of clonal transcript (first loading) 
and the total amount of TCR transcript (second loading). Quantitation was carried out using the 
ImageQuant software. Relative abundance of the clonotypic transcript was calculated as clonotypic 
signal/total signal x 100.
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Results
Primer sequences
Primers were selected aiming at a match to all members o f the BV family in question and 5 mismatches 
to all other families. Furthermore, the amplified products were chosen to be within a limited size range 
(Table 7). Some BV families (BV5, BV6, BV12, and BV13) were amplified using two different BV 
primers in order to match all members o f these BV families. Because the amplification o f BV13 was 
inhibited by the presence of both BV 13-primers in the same tube, amplification o f the BV13 family 
was carried out in two different reaction tubes.
Melting maps
Using the computer algorithm MELT87 melting maps for each amplified TCRBV region were 
calculated for the theoretical ability to resolve using standardised conditions. For most o f the 24 BV- 
regions a suitable melting profile could be obtained by the attachment o f a 50 bp “GC-clamp” to the 5 - 
end of the constant region primer BCseq2 (Fig 7). A short GC” clamp (8-16 bp) was added to the 5 - 
end o f some BV-primers (BVl and BV21) to modulate the melting profile (Table 7).
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Figure 7. Melting profile o f a BV21 PCR product without clamp (black), with 50 bp 3 -clamp (green) 
and with both 5 '- and 3 -clamp (red) (Table 7).
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Table 7. TCRB Oligonucleotide primers for DGGE analysis.
BV Sequence Pos. Size AG Tm
BVl 5 '-(GC^)-ACTCTGA ACTAA ACCTG A-3 ' -55 199 -41.3 51.2
BV2 5 -TCAACCATGCAAGCCTGACC-3 ' -74 212 -39.3 55.7
BV3 5 '-CGCTTCTCCCTGATTCTGG AGTCC-3 ' -54 192 -47.1 61.2
BV4 5 '-TTCCCATCAGCCGCCCAAACCTA-3 ' -81 219 -49.9 65.0
BV5 5 '-CTGAG ATGAATGTGAGCACCTTG-3 ' -51 189 -39.8 53.9
5 '-CTGAGCTG AATGTGAACGCCTTG-3 ' -51 189 -43.4 58.6
BV6 5 -AGATCCAGCGCACAGAGCG-3 ' -41 179 -39.3 56.2
5 -AGATCCAGCGCACASAGCA-3 ' -41 179 -37.6 54.9
BV7 5 '-GCCA AGTCGCTTCTC ACCTG-3 ' -90 228 -39.3 54.8
BV8 5'-TGAAGATCCAGCCCTCAGAACCC-3' -43 181 -45.3 60.2
BV9 5 '-CTTCACATCAATTCCCTGGAGA-3 ' -45 183 -39.7 53.1
BVIO 5 '-CCACGG AGTCAGGGGACACA-3 ' -32 170 -39.9 57.8
B V ll 5' TGCCAGGCCCTCACATACCTCTCA-3' -31 169 -47.4 63.5
BV12 5 '-GAGAATTTCCTCCTCACTCTGG-3 ' -47 185 -39.2 51.2
5 -GACCTCCCCCTCACTCTGG-3 ' -44 182 -37.8 53.0
BV13 5 -CTCAGGCTGCTGTCGGCTG-3 ' -45 183 -39.2 56.8
5 '-CTCAGGCTGGAGTTGGCTG-3 ' -45 183 -37.5 53.1
BV14 5 '-AGGGTACAAAGTCTCTCG AAA AG-3 ' -84 222 -40.4 50.7
BV15 5 '-CAGGCACAGGCTAA ATTCTCC-3 ' -65 203 -40.2 53.1
BV16 5 '-(GC' ')-GGCGAACTGGAGG ATTCTGGAGT-3 ' -30 181 -42.0 55.4
BV17 5 '-GAAGGGTACAGCGTCTCTCGG-3 ' -87 225 -41.0 55.3
BV18 5 '-TTTCTGCTGAA'TTTCCCA AAGAGG-3 ' -81 219 -45.7 57.7
BVI9 5 '-TCTCAATGCCCCA AGAACGCAC-3 ' -74 212 -44.5 60.8
BV20 5 '-AGGTGCCCCAGAATCTCTCAG-3 ' -95 233 -40.3 54.7
BV21 5 '-(GC^)-GCTCAAAGGAGTAGACTCCACTCTC-3 ' -65 211 -42.5 53.9
BV22 5 '-AGATCCGGTCCACAAAGCTG-3 ' -35 173 -39.2 54.0
BV23 5 -ATTCTGAACTGAACATGAGCTCCT-3 ' -53 191 -41.1 53.0
BV24 5 -ATCCAGGAGGCCGAACACTTC-3 ' -77 215 -42.0 56.8
BCseq2 5 '-ACAGCG ACCTCGGGTGGG AA-3 ' 38 -43.4 61.2
BC5' 5 '-TG AGCTGGTGGGTGAATGGG-3 ' 187 343 -40.5 57.9
BC3' 5'-GGTGGCCTTCCCTAGCAGG-3' 
BCseq2-GC
530 -40.7 55.9
5’-GCCGCCCGCCGCTCGCCCGCCGCGCCCCTGCCCGCCGCCCCCGCCCGACAGCGACCTCGGGTGGGAA-3
Position +1 is defined as the first nucleotide after the sequence coding for the conserved amino acid 
sequence CASS in the proximal end of the variable domain. The approximate sizes of the PCR products 
are calculated using an estimated mean length of the DJ region of 50 bp.
DGGE analysis of cloned TCRBVl-24
Cloned TCR transcripts were PCR amplified and subjected to DGGE analysis to investigate whether it 
was possible to resolve all 25 products in the same gel using standardised conditions. For each TCRBV 
family several individual clones were amplified, and a minimum of 4 different clones were evaluated 
by DGGE. In all cases it was possible to resolve the product as a distinct band in the gel (Fig. 8).
To investigate the ability of the method to distinguish between different clones carrying the same 
TCRBV region, 16 different TCRBV13 clones were amplified and run in the same gel (Fig. 9). The
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results clearly indicate that the method is capable of distinguishing between clones that differ only in 
the junctional region o f the receptor.
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Figure 8 . Denaturing gradient gel analysis of TCR transcripts covering BV families 1-24. PBL cDNA 
was amplified with primers specific for BV families 1-24, cloned into PCR™", reamplified and loaded 
onto a 20% - 80% denaturing gradient gel and run for 4.5 hours at 160 Volts. DNA was stained with 
ethidium bromide and photographed under UV light.
Analysis of PHA and PPD stimulated T cells
To verify that polyclonal T-cell populations will reveal a smear, whereas the presence of clonotypic T 
cells will reveal a distinct band in the gel, T cells were stimulated with PHA and PPD respectively, 
and analysed using DGGE. Prior to DGGE analysis it was tested by agarose gel electrophoresis that all 
25 reactions had successfully amplified products of the correct size without spurious amplification 
products. The results showed that the RT-PCR/DGGE analysis of polyclonal T cells results in a gel 
smear whereas the analysis of PPD stimulated T cells demonstrated the presence o f several distinct 
bands in the gel. Examples of the DGGE analysis o f PHA and PPD stimulated T-cell populations are 
seen in Fig 10.
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Figure 9. DGGE analysis of sixteen cloned TCRBV 13 transcripts. cDNA was prepared from PHA 
activated lymphocytes and the B V l3 transcripts were amplified. Subsequently these B V l3 PCR 
products were cloned into PCR™", reamplified and loaded onto a 20% - 80% denaturing gradient gel 
and run for 4.5 hours at 160 Volts. DNA was stained with ethidium bromide and photographed under 
UV light.
Figure 10. DGGE analysis of T cells stimulated with PPD or PHA. The individual amplifications were 
carried out using equal amounts of TCR cDNA.
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Quantitation of clonotypic transcripts in a heterogeneous background
To investigate the detection level o f DGGE, experiments were carried out to quantitate the fraction o f a 
clonotypic transcript in a mixed T-cell population. This was achieved by mixing at different ratios 
cDNA derived from a T-cell clone with cDNA from PBL. Dual loading at different timepoints enabled 
the quantitation of the clonotypic BVl 7 transcript relative to the total amount o f TCRBV17 (Fig. 11). 
This analysis showed that it is possible to detect clonal transcripts constituting below 2.5% of the total 
amount of PCR product.
Figure 11. Sensitivity of the DGGE method. Clonal TCR cDNA was mixed with cDNA from PHA 
stimulated T cells to enable the quantitation of clonal and polyclonal components in the sample. Upper 
panel shows the sample after 30 min DGGE (prior to sequence dependent separation); lower panel 
shows the sample after 4.5 hour DGGE (after sequence dependent separation) resolving only the clonal 
transcript as a distinct band in the gel. The clonal transcript in the first four lanes was visible under UV 
light, after staining with EtBr.
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Discussion
We have here described a novel approach for detection of a p  T-eell clonality. The method combines 
RT-PCR to selectively amplify 24 TCRBV families, and DGGE to resolve clonotypic T-cell sequences. 
Calculation of melting profiles of randomly selected TCR p sequences formed the basis for selection of 
BV primers that together with a “GC-clamped” constant region primer would amplify all relevant 
sequences and render them suitable for DGGE analysis. The versatility of the assay was demonstrated 
by the absence of bands in the gel when polyclonal populations were analysed. In contrast, the analysis of 
specifically activated T cells, revealed the presence o f numerous bands in each lane; the full analysis 
providing “TCR clonotype maps” of the analysed T-cell population. Distinct bands in the gel were 
detected when cloned transcripts from each of the 24 different TCRBV families were analysed. Several 
cloned BV products from each family were analysed using DGGE, and all of these were resolved as 
distinct bands in the gel. Furthermore, the analysis of 16 different cloned transcripts derived from the 
TCRBV13 family indicated that the present method has the resolving power to distinguish between 
most clonal transcripts derived from the same TCRBV family. Obviously, situations may occur in which 
two different transcripts retard too close to each other to be recovered from the gel or even be distinguished 
as separate bands using “broad range” DGGE parameters (164). Our analysis of cloned TCR transcripts 
nevertheless indicates that it is a rare situation to have two different sequences that cannot be clearly 
distinguished as separate bands. This also makes the present method ideal for analysis of in vitro 
established T-eell clones carrying the same BV region. When the amplified products are run in the 
same gel, the specific individual band pattern will reveal whether or not the clones are sister clones.
Most analyses of T-cell clonality focus on the examination of pathological tissues for the 
presence o f clonotypic T cells. An important aspect is therefore related to the sensitivity o f the method. 
Using DGGE, clonotypic transcripts that constitute only a minority of the T cells carrying the specific 
BV-region will be revealed in the gel. Clonotypic transcripts constituting as low as 2.5% of the BV 
region in question can easily be visualised in the gel by ethidium bromide staining. Assuming that all 
regions are expressed at equal levels, this means that a T-cell clone can be detected in a mixed 
population at a fraction of 0 . 1  %.
49
At present, all methods for the analysis of clonality in TCRBV regions involve different steps 
o f either blotting, re-amplification, radioactive labeling or exposure to autoradiographs (159-161; 165). 
The DGGE based method described here requires none o f these steps and visualisation of the amplified 
DNA is accomplished by means of simple staining with EtBr. The method is therefore simple and fast 
and includes steps that can easily be set up for routine analysis, even in more modestly equipped 
laboratories. The described method may provide a powerful tool to monitor T-cell responses in 
connection with vaccination protocols, immunotherapeutic transfusion o f T cells, and other situations 
where a T-cell clone is present as a minority in an otherwise polyclonal T-cell population.
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Local versus systemic immune reactions against disseminated melanoma; 
predominance of localised clonotypic T-cell expansions
Abstract
It is well established that melanoma cells express antigens that are recognised by autologous T-cells.
In terms of the in vivo T-cell response, current insight is however limited, and little is known with 
regards to the detailed characteristics of the T-cell response. In the present study we have used TCR 
clonotype mapping for detailed characterisation of the in situ T-cell response against human 
melanoma.
Analysis of six subcutaneous métastasés from two patients revealed the presence o f multiple 
clonotypic T-cells in all lesions, the number o f T-cell clonotypes ranging from thirty to more than 
forty in each lesion. The same lesions were analysed for the relative expression of TCRBV regions 1- 
24 demonstrating that clonotypic T cells were present in regions expressed at both high and low levels. 
Comparison of the T-cell clonotypes present in the three lesions from each patient demonstrated that 
most clonotypes were exclusively detected in a single lesion.
The present data indicate that in vivo anti-melanoma T-cell responses are much more 
heterogeneous than previously appreciated and accommodate a predominance o f strictly localised T- 
cell clonotypes.
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Introduction
Melanoma cells are considered to be immunogenic and T cells often infiltrate melanoma lesions. 
Although the direct evidence o f the therapeutic significance of these T cells is still lacking, a number 
o f clinical observations, e.g. the higher risk of melanoma for immune-suppressed individuals and the 
induced regression of metastatic lesions subsequent to immunotherapy (128; 129), strongly indicate a 
functional relevance o f the T cells. It has been shown that the immune responses to melanoma include 
CTL capable of lysing autologous melanoma cells in vitro, and recently a number o f melanoma 
associated antigens have been characterised and the peptide epitopes defined (65). However, it is not 
known whether these antigens are capable of inducing T-cell responses in vivo. Analyses o f the in vivo 
T-cell response have suggested the involvement of clonotypic T cells in the immunological response 
to malignant melanoma. Still, most studies have been limited to the analysis of T-cell clonality in sub­
populations of TIL expressing specific TCRBV regions at a significant level (102; 103).
Consequently, current knowledge is limited in terms of the heterogeneity o f the T-cell infiltrate and 
the numbers o f T-cell clones engaged with in vivo responses against melanoma.
Complete and detailed analyses have been hampered by the lack o f methods capable of 
detecting clonotypic T cells with high sensitivity in a heterogeneous background. In the present study, 
we have used a recently developed, highly sensitive method based on RT-PCR and DGGE to analyse 
for the presence o f clonotypic T cells in six subcutaneous melanoma lesions from two patients. We 
demonstrate that the T-cell infiltrate in melanoma is exceedingly heterogeneous and accommodate a 
much larger number o f T-cell clonotypes than previously appreciated. Using a semi-quantitative RT- 
PCR methodology we further examined the TCRBV repertoire and established that T-cell clonotypes 
may be detected in BV regions expressed at high as well as low levels. Furthermore, we demonstrate 
that any specific T-cell clonotype is in most cases exclusively present in a single lesion only, 
indicating that the T-cell infiltrate in melanoma recruits a predominance of localised clonotypic T 
cells.
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Materials and Methods
Tumour Samples
Fresh subcutaneous melanoma lesions were received as biopsy material immediately after surgery 
performed at the Department o f Plastic Surgery, University Hospital, Copenhagen (patient #1) and 
Department o f Dermatology, School of Medicine, D-97080 Würzburg, Germany (patient #2). PBL 
were used for tissue typing. Tumour lesions and blood samples were taken from the respective patients 
at the same time point.
Immunohistology
Frozen sections were fixed in cold acetone for 10 minutes followed by removal of endogenous 
peroxidase with 0.03% H2O2, and blocking of collagenous elements with 10% species specific serum 
in 1% BSA/PBS. The antibodies were then overlayed onto serial sections, at predetermined dilutions 
(usually 20 pg/ml) and the slides were incubated in a humid chamber for 30 minutes. With PBS 
washes between every step, a biotinylated link antibody was applied for 1 0  minutes followed by a 
streptavidin-linked enzyme, i.e. either peroxidase or alkaline phosphatase, for 10 minutes. After 
another wash, the substrate was added and the slides were incubated in the dark for 20 minutes. After a 
wash in PBS, the slides were counter stained, mounted and viewed using an Olympus BH2 
microscope with photographic capabilities. Anti-Vpl3 and V pl4  antibodies are commercially 
available and used according to manufacturer’s guidelines (Immunotech, Westbrook, ME, USA).
RT-PCR for quantitative TCRBV analysis and TCR clonotype mapping
Tumour biopsies and blood samples were processed immediately after surgery. RNA was extracted 
using the Purescript Isolation Kit (Centra Systems Inc. NC). cDNA synthesis and quantitation o f TCR 
cDNA in the each sample were carried as described (136). Using equal amounts of TCR template in 
all reactions cDNA was amplified using separate primer panels for quantitative TCRBV region 
analysis (136) and for TCR clonotype mapping (166). Amplifications were carried out in a total 
volume of 25 pi containing IxPCR buffer (50mM KCl, 20 mM Tris pH 8.4, 2.0 mM M gC f, 0.2 mM
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cresol red, 12% sucrose, 0.005% (w/v) BSA (Boehringer-Mannheim, Mannheim, Germany)), 2.5 pmol 
of each primer, 40 mM dNTPs (Pharmacia LKB, Uppsala, Sweden) and 1.25 units of AmpliTaq 
polymerase (Perkin Elmer Cetus Corporation, Emeryville, CA.). Parameters used for the amplification 
were 94°C for 60 sec, 60°C for 60 sec. and 72°C for 60 sec. for 32 (quantitative PCR) or 40 cycles 
(DGGE). Taq polymerase and dNTPs were added to the reaction tube at an 80°C step between the 
dénaturation and annealing steps of the first cycle (Hot start).
For quantitative analysis, the constant region primer was labeled with ^^P. Ten-microliter 
aliquots o f PCR products were electrophoresed in a 2% NuSieve 3:1 agarose gel (FMC BioProducts, 
Rockland, ME) which was subsequently dried under vacuum and exposed to a Molecular Dynamics 
Storage Phosphor Screen (Molecular Dynamics, Sunnyvale, CA). Quantitation was accomplished 
using the Imagequant software (137).
For DGGE analysis, lOpl aliquots were loaded onto a denaturing gradient gel containing 6 % 
polyacrylamide and a gradient o f urea and formamide from 20% to 80%. Gels were run at 160 V for 
4.5 h in Ix TAE buffer kept at a constant temperature of 58°C. After electrophoresis, the gel was 
stained with ethidium bromide and photographed under UV transillumination.
To analyse for the expression of Tyrosinase, MART-l/Melan-A and gplOO, RT-PCR was 
carried out with primers specific for these transcripts, as previously described (109).
Sequencing
To verify sequence identity to DNA bands that resolved at similar positions in the denaturing gradient 
gel, these transcripts were subjected to sequence analysis using the Thermo Sequenase cycle 
sequencing kit (Amersham, Life Science, Cleveland, OH). In brief, bands were excised from the 
denaturing gradient gel, and DNA was eluted in H2O and reamplified. An aliquot (0.2 pi) o f the PCR 
product was used as template in a 40-cycle sequencing reaction with ^^ P labeled Bcseq2 as sequencing 
primer. Gels were dried under vacuum and exposed to a Phosphor Screen.
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Results
RT-PCR for MAAs
To investigate whether the lesions exhibited any differences in the expression of MAA, the six 
biopsies were analysed for the expression of Tyrosinase, MART-1 and gplOO by RT-PCR. All lesions 
were positive for the expression of these transcripts (data not shown).
TCRBV expression
PBL and three subcutaneous melanoma lesions from each patient were analysed for the expression of 
TCRBV regions 1-24 by semi-quantitative RT-PCR. The results from these analyses are given in 
Table 8 . In all lesions, only a limited number of BV regions were expressed at levels significantly 
above what was seen in the PBL from the same patient. However, major differences were detected in 
the level of BV region expression between the different lesions from each patient (e.g. patient #1,
BV6 ; 2.8, 10.1 and 6.0% respectively in lesion 1, 2, and 3; patient #2, BV3, 6 .6 , 10.6, and 3.4% 
respectively in lesion 1, 2, and 3). Although the data for the PBL did not directly indicate the presence 
of clonally expanded T cells in the tumours, the comparison of the different lesions could indicate 
distinct T-cell populations in each lesion.
The patients PBL were used for histological tissue typing (Patient #1 : HLA-Al, A2, B 8 ,
B44, Cw3, Cw5, DR3, DR9, Patient #2 : Not done).
TCR clonotype mapping
PBL and tumour lesions were analysed for the presence of T-cell clonotypes by the DGGE based TCR 
clonotype mapping. Analysis o f PBL did not reveal any distinct bands in the denaturing gradient gel 
(Fig. 13, and data not shown). Analysis o f tumour samples, however, showed the presence of multiple 
clonotypic TCR transcripts covering the majority of the TCRBV regions 1-24. In all lesions more than 
thirty clonotypes were detected and in lesion 3 from patient #2 an exceedingly high number of 
clonotypes was detected (Fig. 12, and Table 8 ). Comparing the number o f clonotypes and the relative
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Figure 12. TCR clonotype maps of melanoma biopsy. cDNA from tumour tissues and peripheral blood 
lymphocytes were amplified with primers specific for BV families 1-24 and aliquots loaded onto a 
20% - 80% denaturing gradient gel and run for 4.5 hours at 160 Volts at a constant temperature of 
58°C.
expression of the different BV regions clearly demonstrated that clonotypic transcripts were detected 
in regions expressed at high as well as low levels.
To investigate whether specific T-cell clonotypes could be detected in more than a single 
lesion, the DGGE analysis was repeated and samples loaded in adjacent lanes of the denaturing 
gradient gel. As depicted in Fig. 13, most of the clonotypes were exclusively present in a single lesion. 
More than fifty clonal TCR transcripts were compared of which six appeared to be accumulated in two 
different lesions. None o f the clonotypes were present in all three lesions from the same patient.
Sequencing
A number of transcripts were detected that resolved at positions in the gel indicating sequence identity 
(Fig. 13). These DNA bands were therefore subjected to sequence analysis, including Patient #1: BV4 
-  lesion 1 (lower band) and lesion 3 (lower band), different sequences; B V l6  -  lesion 1 (upper band) 
and lesion 3 (second upper band), different sequences; BV22 -  lesion 1 (lower band) and lesion 2 
(lower band), identical sequence; BV22 - lesion 1 (second lower band) and lesion 3 (lower band).
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identical sequences; BV24- lesion 2 and 3, (second and third lower band respectively), identical 
sequences. Patient #2: BV14 -  lesion 1 (second lower band), lesion 3 (lower band), identical
Patient #1 Patient #2
BV4 BV16 BV22 BV24 BV8 BV14
Figure 13. Comparative DGGE analysis of specific T-cell clonotypes in lesions 1-3 (L1-L3) from the 
two patients
sequences). Out o f six potentially identical sequences, only four of these were indeed identical. It 
should be noted that the two different BV4 sequences derived from patient #1, lesions #1 and #3, 
shared the same joining sequence, were of identical length, and only differed in the junction between 
the variable and the joining region.
Immunohistology
The immunological staining with monoclonal antibodies specific for B V l3 or B V l4 in lesion #3 from 
patient # 1  demonstrated that positive cells were cells not present through out the tumor, but present as 
clusters o f cells. Only a limited number of singly positive stained cells were present indicating that the 
T cells are activated and expand but do not migrate to other parts of the tumor.
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Figure 14. Immunohistology o f lesion #3 from patient #1, using anti-Vpi3 (left) or anti-Vp 14 specific 
antibody.
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Discussion
During the past decade important insights has been unveiled into the role of T lymphocytes in the host's 
immune response to cancer in general and to melanoma in particular (64). A number of melanoma 
associated antigens have been characterised which are specifically recognised by autologous T cells in the 
context o f HLA molecules (65) and precursor T cells specific for melanoma associated antigens, have 
been isolated from PBL of melanoma patients (72). Several clinical observations, e.g., the 
immunologically mediated partial regression of primary melanoma (167) and the higher risk of immune 
suppressed individuals for malignant melanoma (168), indicate the relevance of the host immune 
responses for the control of melanoma progression. The notion that a functional and specific T-cell 
response may be operating in melanoma patients was reinforced by the demonstration of clonotypic T 
cells in both primary and metastatic melanoma lesions (108; 150). Although our knowledge of the T-cell 
response against melanoma has increased considerably, only few attempts have been made to characterise 
in detail the complexity o f the in vivo T-cell response and very little is known about the number of clones 
involved in the T-cell response and the TCRBV regions expressed by these clones. It therefore remains 
elusive whether specific clones or BV families participate in a systemic T-cell response against tumour 
burden at different anatomical sites in the same patient.
In the present study we have attempted to answer some of these questions using TCR 
clonotype mapping. The analysis of the melanoma lesions revealed the presence of multiple clonotypic 
TCR transcripts (Fig. 12), the numbers of clonotypes ranging from approximately thirty up to more 
than forty (Table 8 ).
Previous studies have been limited to analyse for the presence of clonotypic T-cells in highly 
expressed BV regions (102; 105; 150). In contrast, here we analysed the BV regions 1-24, not 
discriminating by the level of expression. This approach revealed that clonal T cells do exist in most 
BV regions irrespective o f the level of expression (Table 8 ). Puisieux et al. (169) analysed melanoma 
lesions for the presence o f T-cell clonality by determining the VDJ junction size patterns of TIL. This 
approach did not reveal the same degree of clonotypic complexity as in the present study, suggesting 
that VDJ junction size patterns may not always reflect the true number of individual clonal
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expansions. When several clones carrying the same BV region are present in a T-cell population, the 
accurate detection of clonality by determining the VDJ junction sizes may be hampered. TCR 
clonotype mapping separates clonotypic transcripts according to their melting properties, implying that 
transcripts, which differ in primary sequence, will be resolved at different positions in the gel 
independently o f the length o f the transcript.
The present data suggests that the in situ T-cell response against malignant melanoma is 
highly complex and involves a much higher number of T-cell clones than previously appreciated. By 
repertoire analysis (170) or more recently, by tetrameric MHC-peptide complex analysis (171; 172) 
the numbers o f virus specific T cells during primary infection were shown to be much greater than 
previously appreciated. The present data suggest that the numbers of different T-cell clones involved 
in responses to tumour antigens may be of unexpected high magnitude. Whether the high number of 
T-cell clonotypes in the melanoma lesions reflects the recognition o f multiple different melanoma 
associated peptide antigens remains elusive. It could be speculated that the list of melanoma antigens 
recognised by T cells characterised so far is not yet complete. In this respect it is interesting that most 
antigens characterised to date have been identified using in vitro expanded TIL. Recent data suggests 
that in vitro culture may eliminate prominent in vivo T-cell populations indicating that in vitro  TIL 
inadequately reflects the in vivo situation (106; 173). Furthermore, to our knowledge, no compelling 
data are available with respect to antigens recognised by T cells in situ.
The high number of clones present in the lesions prompted us to investigate in detail the 
location and area of distribution of specific T-cell clones in the lesions. Immunohistology revealed the 
presence o f numerous T cells throughout the tumour (data not shown). However, the use o f specific 
antibodies against TCRBV regions clearly demonstrated that the T-cell clones expressing these 
regions were located as clusters of cells (Fig. 14) suggesting a local clonal expansion.
To investigate further whether T cells clonally expanded in situ were local by nature, we compared the 
clonotypes detected in the different lesions from each patient, with the aim of resolving whether 
specific T-cell clones were identical, i.e. originated from the same clonal expansion. We therefore 
employed TCR clonotype mapping for a comparative analysis of specific T-cell clonotypes in the 
different lesions. The results demonstrated that the preponderance of the clonotypes were exclusively
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located in a single lesion only (Fig 14). The in vivo accumulation of the same T-cell clone in different 
métastasés has been reported (169; 174). The present study corroborates these findings, as a minority 
o f the detected T-cell clonotypes was present in two lesions (Fig. 13). Nevertheless, our data indicate 
that the vast majority o f the T-cell clones do not accumulate at several metastatic sites.
These data, together with the fact that clonotypic T cells were not detected in the blood 
samples, indicate that the T-cell response is initiated and executed by local T-cells that become 
activated and expand clonally, but do not enter the periphery. Alternatively, it is possible that clonally 
expanded T cells, if they enter the periphery, have been through multiple cell cycles and therefore 
reach an anergic or senescent state upon arrival to other metastatic lesions.
The general conclusions from the present study are that the T-cell infiltrate of malignant 
melanoma is exceedingly heterogeneous and contrived by a much higher number o f different 
clonotypic T cells than previously appreciated. Furthermore, our data indicate that the vast majority of 
clonotypic T cells in melanoma TIL, at least in the case of subcutaneous metastasis, may be 
considered as strictly local.
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Clonotypic T-cell expansion induced by melanoma: comparison of 
the in vivo and in vitro situation
Abstract
Melanoma is generally accepted as being antigenic and capable of eliciting T-cell responses, which 
however, in most cases are inadequate to control tumour growth. Several studies have focused on the 
analysis of TIL and demonstrated overexpression of specific TCR variable regions due to clonal 
expansions o f T cells. We recently reported the development of a new technique based on RT-PCR 
and DGGE, which allows the detection of clonally expanded T cells with high sensitivity. Using this 
method we were able to demonstrate that the T-cell infiltrate in melanoma is exceedingly 
heterogeneous and contains a higher number of T-cell clonotypes than previously appreciated.
Here, we report the analysis of a subcutaneous melanoma metastasis and a cytotoxic T-cell 
line, TIL92, derived from this lesion, for the presence of clonally expanded T cells. A high number of 
T-cell clonotypes was demonstrated in the tumour, whereas TIL92 consisted o f only a limited number 
o f T-cell clones. Furthermore, the majority of the T-cell clonotypes detected in the lesion were 
different from those expanded in TIL92. Our data indicate that the heterogeneity of the T-cell infiltrate 
is lost during in vitro culture and that standard culture conditions favour the outgrowth of clonotypes, 
which do not necessarily participate in the in vivo response against melanoma.
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Introduction
There is a consensus that T cells play a major role in the control o f melanoma (175). This consensus is 
based on the demonstration o f tumour-specific T cells and a number of clinical observations, e.g., the 
spontaneous regression of primary tumours and the induced regression of metastatic lesions 
subsequent to immune modulatory therapies. Recently, the fine specificity of in vitro expanded anti­
melanoma T cells has been established and the recognised tumour antigens have been defined (176). 
The characterisation o f these antigens has, however, demonstrated the genuinely low immunogenicity 
o f most o f them. Thus, the question of whether in vitro expanded T cells reflect the in vivo immune 
response has been raised (106). So far it has not been possible to answer this question due to 
methodological problems in characterising the in vivo T-cell response. Recent technological advances 
such as the MHC class I tetramer technique (171) or the TCR clonotype mapping (166) have shed 
unexpected light on the nature of T-cell responses to pathogens and tumours. The latter technique 
enabled us to demonstrate that the T-cell infiltrate in melanoma is exceedingly heterogeneous and 
contain a higher number of T-cell clonotypes than previously appreciated (177).
In the present study we have addressed the question of whether clonal T-cell expansions 
occurring in situ are maintained in vitro, using standard culture conditions.
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Materials and Methods
Cell culture
The FM92 melanoma cell line was established from a subcutaneous metastasis processed immediately 
after surgery. Serological tissue typing was performed (HLA-Al, A2, B8 , B44, Cw3, Cw5, DR3,
DR9), and FCM analysis demonstrated that the tumour cells had retained expression of the HLA class 
I molecules (109). Further analysis demonstrated that MART -1 /Melan-A and gplOO were expressed in 
the tumour lesion as well as in FM92, whereas mRNA for tyrosinase was not detectable.
The cytotoxic T-cell line (CTL), TIL92, was established by placing mechanically dispersed 
tumour fragments in 24-well plates (Nunc, Denmark) in RPMI-1640 medium containing 10% FCS. 
Three days later, 20 U/ml Interleukin 2 (IL-2) and 10 U/ml Interleukin 4 (IL-4) were added. The 
addition o f cytokines was repeated every 3-4 days. Cytotoxic activity directed against the autologous 
melanoma cells was present after 10 days of culture (data not shown). Cultures were expanded when 
cell densities reached 2x10^  per well. The cells used in the present study had been in culture for 5 
weeks, at this timepoint they exhibited strong cytotoxicity against the autologous melanoma cell line 
FM92 (data not shown).
TCR clonotype mapping
Tumour material and blood samples were processed immediately after surgery. RNA was extracted 
using the Purescript Isolation Kit (Centra Systems Inc. NC). cDNA synthesis and quantitation o f TCR 
cDNA in the each sample were carried out as described (136). Using equal amounts of TCR template 
in all reactions, cDNA was amplified using primers specific for TCRBV regions 1-24 together with 
the “GC-clamped” constant region primer (166). Amplifications were carried out in a total volume of 
25 pi containing IxPCR buffer (50mM KCl, 20 mM Tris pH 8.4, 2.0 mM MgCb, 0.2 mM cresol red, 
12% sucrose, 0.005% (w/v) BSA (Boehringer-Mannheim, Mannheim, Germany)), 2.5 pmol of each 
primer, 40 mM dNTPs (Pharmacia LKB, Uppsala, Sweden) and 1.25 units of AmpliTaq polymerase 
(Perkin Elmer Cetus Corporation, Emeryville, CA.). The parameters used for amplification were 94°C 
for 30 sec, 60°C for 30 sec. and 72°C for 30 sec. for 40 cycles. Taq polymerase and dNTPs were
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added to the reaction tube at a 80°C step between the dénaturation and annealing steps o f the first 
cycle. Gels for DGGE analysis contained 6 % polyacrylamide and a gradient of urea and formamide 
from 20% to 80%, and were run at 160 V for 4.5 h in Ix TAE buffer kept at a constant temperature of 
58°C. After electrophoresis, the gel was stained with ethidium bromide and photographed under UV 
transillumination.
Sequencing reaction
Sequence analysis of PGR products was performed using the Thermo Sequenase cycle sequencing kit 
(Amersham, Life Science, Cleveland, OH) according to the manufacturer’s instructions. In brief, 
bands were excised from the denaturing gradient gel, and DNA was eluted in H2O and reamplified. An 
aliquot (0.2 pi) o f the PCR product was used as template in a 40-cycle sequencing reaction with ^^ P 
labeled constant region sequencing primer. Gels were dried under vacuum and exposed to a Phosphor 
Screen.
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Results
Peripheral blood lymphocytes and a subcutaneous melanoma lesion were subjected to RT-PCR/DGGE 
clonotype mapping. The analysis of PEL revealed very few, faint bands within a background smear, 
suggesting only limited clonal expansions of T cells (Fig. 15 A). In contrast, the tumour was 
characterised by the presence of multiple T-cell clonotypes (Fig. 15B). Clonotypic TCR transcripts 
were demonstrated for the majority of the BV regions. In most cases, several clones was identified for 
each individual BV family. However, for a few BV regions, e.g. BVIO, BVl 1 and BV24, only a single 
clonotype was detected (Fig. 15B).
TIL propagated in vitro often show restricted TCRBV repertoire. In order to examine 
whether the dominant clones isolated in vitro were representative of the in vivo accumulation of T 
cells within the tumour, we performed TCR clonotype mapping of the CTL line TIL92 which was 
established from the melanoma lesion. The results from this DGGE analysis (Fig. 15C) differed 
substantially from the results obtained from the analysis of the tumour lesion. TIL92 showed a low 
degree o f heterogeneity as compared to the tumour lesion, i.e., only a single T-cell clone was present 
for each BV region in most cases. Furthermore, the clonotypes for BV2 and BV5 present in TIL92 
were completely absent in the tumour lesion; vice versa the clonotype for BVIO was present in vivo, 
but was lost during in vitro propagation.
These observations prompted us to test whether the clonotypes detected in TIL92 were 
identical to those present in the tumour from which TIL92 was established. For this purpose we 
repeated the RT-PCR analysis and loaded samples onto a denaturing gradient gel in adjacent lanes.
This direct comparison of the TCR clonotypes present in the tumour and TIL92 demonstrated that 
very few of the clonotypes were identical (Fig. 16). The BV regions BVl 4, B V I6 , BV20 and BV24 
were subjected to sequence analysis to verify potential sequence identity. In all cases sequence identity 
was verified (data not shown).
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Figure 15. TCR clonotype maps of PEL, tumour biopsy and TIL92. cDNA from tumour tissues and 
peripheral blood lymphocytes were amplified with primers specific for BV families 1-24 and aliquots 
loaded onto a 20% - 80% denaturing gradient gel and run for 4.5 hours at 160 Volts at a constant 
temperature of 58°C. DNA was stained with ethidium bromide and photographed under UV light. A, 
PEL; B, Biopsy; C, TIL92.
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Discussion
Antigens recognised by CD4 and CD8  T cells have been identified on melanoma cells (178). Previous 
studies have suggested that antigen-selected TCR repertoires may vaiy in complexity from very limited to 
extremely diverse. These differences reflect at least in part methodological problems in characterising 
the in vivo T-cell response. Although substantial progress in the characterisation o f T-cell responses 
against viruses was made through the introduction of the MHC class I tetramer technique (171), the 
characterisation o f T-cell responses against melanoma still largely depends on the in vitro expansion 
o f T cells. Recent reports demonstrated that tetrameric complexes are suitable to detect and isolate T 
cells recognising known melanoma associated antigens (72). However, characterisation o f the known 
antigens revealed the genuinely low immunogenicity o f most of them (178). The low immunogenicity 
hampers the design o f suitable tetrameric complexes or the application of other highly sensitive 
detection methods, e.g. the IFN-y ELIspot assay to determine the complexity of the T- cell response. 
Still, these new techniques posed the question about the value of in vitro expansion techniques such as 
limiting dilution cloning since the results obtained suggested a more heterogeneous T-cell response 
than hitherto predicted.
In the present study we probed the question whether this in vivo heterogeneity o f the T-cell 
infiltrate is maintained under standard in vitro culture conditions. A subcutaneous melanoma 
metastasis and a cytotoxic T-cell line, TIL92, established from this metastasis were analysed for the 
presence of clonally expanded T cells. A complex and highly diverse pattern of T-cell clonotypes was 
demonstrated in the melanoma lesion, in contrast to TIL92 in which only a limited number of 
clonotypes were detected. Furthermore, the vast majority of the T-cell clonotypes detected in the 
tumour lesion were shown to be different from those present in TIL92.
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Figure 16. Comparative DGGE analysis of T-cell clonotypes in tumour biopsy and TIL92. To compare 
the T-cell clonotypes in biopsy and TIL92, amplified cDNA were loaded onto a 20% - 80% denaturing 
gradient gel in adjacent lanes, and run for 4.5 hours at 160 Volts at a constant temperature of 58°C. 
DNA was stained with ethidium bromide and photographed under UV light.
In corroboration with the data presented here, several recent studies raised the concern 
whether the T-cell clones isolated in vitro are representative of the population within the tumours, 
rather than being a reflection of an in vitro selection (106; 173). The latter has been indicated from 
dramatic changes in the BV region repertoire upon in vitro culture (144). We observed the appearance 
o f specific BV regions in TIL92, i.e., BV2 and BV5, not present in the tumour lesion (Fig 15, B and 
C). However, several BV regions detected in TIL92 were also present in the tumour lesion, including 
BV3, BV4, BV7, BVl I, BVI4, BV16, BV17, BV20, BV22 and BV24. Dufour et al. reported the in 
vitro propagation of a T-cell clone sharing the same BV region as detected in vivo by means of the 
immunoscope approach (179). However, the direct proof of clonotypic identity lacked in this study 
since no sequence data were provided.
The dramatic clonotypic changes demonstrated here by RT-PCR/DGGE based TCR 
clonotype mapping indicate that analysis of the BV region usage alone does not reliably reflect the 
true extent of the changes induced by in vitro culture. This observation may reflect that a large 
proportion of tumour-specific T cells become anergic in the tumour microenvironment (180; 181) and 
consequently become overgrown by the remaining T cells activated during in vitro culture conditions. 
Alternatively, clonotypes detected in tumour specimens represent T-cell clones, which have undergone 
multiple cell divisions. These clones are more likely to reach senescence during in vitro culture than T 
cells that have not been clonally expanded in vivo (182).
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In conclusion, the maze of the in vivo T-cell response against melanoma may be lost during 
in vitro culture. This raise the question of whether tumour associated antigens identified by means o f 
in vitro expanded T cells represent tumour regression antigens relevant for the in vivo situation.
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Concluding remarks and perspectives
Since the first reports on clonotypic in vivo T cells in melanoma were published some five years ago 
(102; 183), the concept of the specific recognition of melanoma associated antigens by T cells has 
become generally approved. The present Thesis adds new insight into the nature of the T-cell response 
against melanoma.
The data presented in paper 1 demonstrate that clonotypic T cells are present in both 
regressive and progressive parts of the same primary melanoma lesions. Using the DGGE based 
methodology, we demonstrate in paper 3 that the T-cell infiltrate in melanoma is exceedingly 
heterogeneous and includes a much higher number o f T-cell clonotypes than previously appreciated. 
Furthermore, paper 3 indicates that the vast majority of these T-cell clonotypes are strictly local in 
their distribution. In paper 4 we demonstrate that normal in vitro culture conditions do not support the 
growth o f in vivo expanded T cells.
The specific aim of paper 1 was to investigate whether the progressive parts of tumours 
would give rise to clonal T-cell responses. Loss of HLA molecules is generally accepted to be a means 
o f immune escape used by melanoma cells and the lack of clonal T-cells in progressive parts of the 
tumour would support this assumption. Our data, however, suggest that HLA restricted T-cell 
responses do take place in both regressive and progressive parts of the lesions indicating that loss of 
molecules involved in the presentation or processing of antigens is an infrequent mechanism of 
immune escape in melanoma. Nevertheless, melanomas may in some cases lose the expression of class 
I molecules. Interestingly, in cell lines established from patients undergoing immunotherapy the losses 
HLA expression is more frequent (184), supplying indicative evidence to the concept of immune 
surveillance by T cells.
The study described in paper 1 was performed by analyses of TIL in primary melanoma 
lesions. Studies investigating the mechanisms of immune escape in melanoma are often conducted 
using late stage metastatic lesions or melanoma cell lines established from metastatic lesions (185- 
187). It could be speculated that in vitro cell lines are exposed to an immunological selection during 
establishment, which is quite different from the immunological selection pressure in vivo. The
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outgrowth of T-cell clonotypes in vitro, which were not expanded in situ could indicate such a 
scenario (106; 173; 188). Melanoma cell lines may therefore not be suited for such studies. In some 
cases the same applies to the use of lesions from late stage melanoma patients. In this respect it is 
interesting that the expression of Fas ligand by melanoma cells, initially reported to be expressed in 7 
out of 7 melanoma lesions (189), has recently been found to be expressed, and only weakly, in only a 
fraction of primary tumours (10%) (190). Although these data do not imply that FasL expression by 
melanoma cells is not involved in immune escape, it should be kept in mind that T cells have other 
means o f killing than the Fas/FasL system and that the mechanisms used by TIL in situ are not known. 
Recently, it was shown that in vitro CTL clones are resistant to FasL induced apoptosis and that these 
clones mediate cytotoxicity independent of Fas/FasL ligation (191).
One o f the suggested immune escape mechanisms in melanoma is the downregulation o f the 
(^-chain o f the TCR/CD3 complex. Only a single study of the (^-chain level in TIL and PEL in 
melanoma patients has been published, and all patients included in this study were suffering from 
metastatic melanoma (110). It could be speculated that the downregulation of the ^-chain may not be 
directly accomplished by the tumour but could be a more general characteristic o f long lasting immune 
responses that are unsuccessful in clearing the antigen from the body, inducing a state o f chronic 
inflammation (192; 193). If this is the case, downregulation of the (!^-chain is secondary to immune 
escape, merely being the result of having an unsuccessful ongoing immune response.
The model o f partially regressing melanoma offers an ideal system to investigate the nature 
o f early events in successful and unsuccessful immune responses against melanoma. Future plans 
using this model include investigations into the level of Thl/Th2 cytokines (194; 195), the expression 
of killer inhibitory receptors (KIRs) by TIL of melanoma (81; 196) and the expression o f the inhibitor 
of NK cell lytic activity, HLA-G, by melanoma cells (197).
The high number o f T-cell clonotypes in melanoma lesions (as demonstrated in paper 3) by 
far exceeds the number o f clonotypes previously detected in melanoma and other tumours (161; 169). 
Most analyses have been carried out by using the “Immunoscope” technique. This method reveals T- 
cell clones by the detection of TCR transcripts which have the same length. As with DGGE/TCR
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clonotype mapping, the “Immunoscope” technique is initiated with a specific amplification of each 
BV family. The size distribution of the DNA molecules withheld in each PCR product is at this point 
evaluated, and only PCR products having a restricted length pattern are further analysed.
Consequently, this approach may not be suitable for the analysis of highly heterogeneous infiltrates.
As it appears from the data obtained with the DGGE/TCR clonotype mapping (Fig. 12, page 57 and 
Fig. 15C, page 68), each BV family may repudiate a number o f clonotypic TCR transcripts of 
unknown length. It could be speculated that the size profile of these PCR products does not differ 
much from the profile obtained from the analysis of PBL, thereby leaving clonotypic transcripts 
undetected. Both methods do, however, have their weak points. Using TCR clonotype mapping, 
different clonotypic transcripts with identical melting properties resolve at the same position in the gel, 
thereby underestimating the number of clonotypes. By using the “Immunoscope” method, TCR 
transcripts of identical length will be revealed as a single transcript. However, in contrast to the 
“Immunoscope” method, the TCR clonotype mapping will not leave clonotypic transcripts undetected.
Our data do not discriminate between CD4 and CD8 cells, but it is well known that both cell 
types infiltrate melanoma lesions (198). Most likely, the T-cell clonotypes of the infiltrate therefore 
consists of both CD4 and CD8 T cells. The high degree of heterogeneity and the local nature o f the T 
cells indicates that each T-cell clone does not expand to as high cell numbers as seen in T-cell 
responses against non-self antigens, i.e. virus infections (172; 199). Whether this reflects the site of 
infection/metastasis or the nature of the antigens (non-self/self) is not known, but the frequent 
development o f lymph node métastasés without the presence of high numbers o f MAA specific T cells 
in the blood (200) indicates that the nature of the antigen is important; non-self antigens being capable 
of eliciting a much stronger T-cell response than self antigens. Although the number of viral peptide 
antigens presented on an infected cell during infection probably exceeds the number of melanoma 
peptides on a melanoma cells, it is conceivable that TCRs with high affinity against dominant self­
determinants, binding with high affinity to the HLA molecule, have been negatively selected against in 
the thymus. It can therefore be speculated that the T-cell response against melanoma is directed 
against determinants that are only present at rather low levels on the cell surface of the melanoma cell. 
Although highly efficient cytotoxic T cells may be established in vitro against such epitopes, it should
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be kept in mind that peptide recognition is much more efficient in the effector phase than in the phase 
o f induction. Furthermore, it is possible that the in situ expression of some antigens is lower than their 
expression in vitro. It is therefore conceivable that some in vivo TIL are only partially activated due to 
a low amount of (sub-dominant) antigen on the cell surface.
As mentioned in the Introduction of this Thesis, a high number o f MAA have been 
characterised that theoretically would give rise to an efficient T-cell response. The reason for the lack 
of such a response could very well differ from antigen to antigen and therefore involve a number of 
different mechanisms. Regarding the apparently low immunogenecity o f proteins of the MAGE 
family, this was recently suggested to be caused by structures in these proteins that are resistant to 
proteolytic degradation, thereby hindering formation of the antigenic peptide in sufficient amounts 
(178).
For the M ART-127.35 peptide it has been indicated that molecular mimicry from other self­
proteins gives rise to peptide antagonists and partial agonists and that these epitopes are involved in 
the maintenance o f the CTL but are impairing the anti-tumour response (201).
In conclusion, data are lacking that prove the prevalent use o f immune escape mechanisms at 
an early stage in melanoma progression, and most antigens characterised are of low immunogenecity. 
Possibly the reason for the rarity of HLA losses, antigen losses and other suggested mechanisms of 
immune escape is that the immune response for a number of reasons is too weak and fails to promote 
the development o f these variants.
The high degree o f heterogeneity of the T-cell infiltrate as demonstrated in paper 3 indicate 
that a high number of different epitopes are being recognised. It is now generally accepted that several 
different TCRs may be utilised that recognise the same peptide epitope, but the presence of more than 
30 different clonal T-cell expansions in each lesion nevertheless indicates a broad spectrum of 
antigens. Equally striking is the local nature of the vast majority of these clones. The recent 
development o f the MHC class I tetramer technique (171) has been used for the detection of MAA 
specific T cells in the blood (72). However, the local nature of the T-cell clones as demonstrated in the 
paper 3 raises the question o f whether clonotypes detected in the blood are in all cases relevant to the 
in situ recognition of tumour cells.
75
An important issue that needs further study is to resolve the question of which antigens are 
recognised by TEL in situ. In vitro studies using CTL lines established from TEL or PBL seem to 
indicate that lines specific for melanocyte differentiation antigens are much easier to establish than 
lines specific for cancer/testis specific antigens i.e. the MAGE family of proteins. The involvement of 
melanocyte differentiation antigens in the in situ recognition is also indicated by the depigmentation 
observed in some patients receiving immunotherapy (202). Recently we have used the DGGE 
methodology to demonstrate the in vivo accumulation of the same T-cell clone in a primary melanoma 
and a vitiligo-like halo about the tumour likewise indicating the involvement of T cells recognising 
normal melanocytes (203). However, apart from these indications as to the group of antigens involved, 
the specific targets of in vivo recognition have not been determined.
The data presented in paper 4 demonstrate that standard in vitro culture conditions of TEL do 
not support the growth of in situ expanded T cells. The complete loss of the in vivo heterogeneity of 
the T-cell infiltrate during in vitro culture clearly illustrates the differences between in vitro and in 
vivo conditions, and raises the question of whether antigens characterised using in vitro CTL are 
relevant for the in vivo situation. Future studies will therefore focus on the establishment of in vitro 
culture conditions that allow the growth of in situ expanded T cells and the use of these T eells for 
subsequent determination of the antigens recognised by T cells in situ.
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